Sentence|AE|Drug
Intravenous azithromycin-induced ototoxicity.|ototoxicity|azithromycin
Immobilization, while Paget's bone disease was present, and perhaps enhanced activation of dihydrotachysterol by rifampicin, could have led to increased calcium-release into the circulation.|increased calcium-release|dihydrotachysterol
Unaccountable severe hypercalcemia in a patient treated for hypoparathyroidism with dihydrotachysterol.|hypercalcemia|dihydrotachysterol
METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.|pseudoporphyria|naproxen
METHODS: We report two cases of pseudoporphyria caused by naproxen and oxaprozin.|pseudoporphyria|oxaprozin
Naproxen, the most common offender, has been associated with a dimorphic clinical pattern: a PCT-like presentation and one simulating erythropoietic protoporphyria in the pediatric population.|erythropoietic protoporphyria|Naproxen
RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.|cutaneous fragility|naproxen
RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.|cutaneous fragility|oxaprozin
RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.|tense bullae|naproxen
RESULTS: A 44-year-old man taking naproxen for chronic low back pain and a 20-year-old woman on oxaprozin for rheumatoid arthritis presented with tense bullae and cutaneous fragility on the face and the back of the hands.|tense bullae|oxaprozin
BACKGROUND: How to best treat psychotic patients who have had past clozapine-induced agranulocytosis or granulocytopenia remains a problem.|granulocytopenia|clozapine
CONCLUSION: The results suggest that olanzapine may be useful in treating patients with clozapine-induced granulocytopenia without the risk of recurrence of hematologic side effects.|granulocytopenia|clozapine
Prolonged severe 5-fluorouracil-associated neurotoxicity in a patient with dihydropyrimidine dehydrogenase deficiency.|neurotoxicity|5-fluorouracil
We describe the side effects of 5-FU in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit.|neurologic toxicity|5-FU
We describe the side effects of 5-FU in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit.|prolonged myelosuppression|5-FU
We describe the side effects of 5-FU in a colon cancer patient who suffered severe mucositis, desquamating dermatitis, prolonged myelosuppression, and neurologic toxicity that required admission to the intensive care unit.|severe mucositis|5-FU
This case suggests that BH-AC, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible encephalopathy syndrome.|encephalopathy syndrome|BH-AC
We report a case of reversible encephalopathy syndrome in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin.|encephalopathy syndrome|BH-AC
We report a case of reversible encephalopathy syndrome in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin.|encephalopathy syndrome|idarubicin
In one case, the readministration of riluzole was followed by the relapse of hepatitis.|hepatitis|riluzole
We report the cases of two patients who developed acute hepatitis after taking riluzole at the recommended dose (100 mg daily) for 7 and 4 weeks, respectively.|hepatitis|riluzole
Lupus-like syndrome caused by 5-aminosalicylic acid in patients with inflammatory bowel disease.|Lupus-like syndrome|5-aminosalicylic acid
Although the two local anesthetics usually do not cause methemoglobinemia, we suspect that the displacement of lidocaine from protein binding by bupivacaine, in combination with metabolic acidosis and treatment with other oxidants, was the reason for the development of methemoglobinemia.|methemoglobinemia|lidocaine
Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.|Methemoglobinemia|bupivacaine
Methemoglobinemia after axillary block with bupivacaine and additional injection of lidocaine in the operative field.|Methemoglobinemia|lidocaine
We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.|methemoglobinemia|bupivacaine
We report a patient with chronic renal failure and ischemic heart disease who developed clinically significant methemoglobinemia after an axillary block with bupivacaine and additional injection of lidocaine in the operative field.|methemoglobinemia|lidocaine
Detection of activated eosinophils in nasal polyps of an aspirin-induced asthma patient.|asthma|aspirin
An episode of subacute encephalopathy after the infusion of a moderate dose of methotrexate (1500 mg/m2) (MTX) is reported in a young adult with metastastic gastric cancer.|encephalopathy|methotrexate
We believe that this represents an unusual case of moderate-dose MTX-induced neurotoxicity in a patient with gastric cancer, which has not previously been reported.|neurotoxicity|MTX
We describe a life threatening side effect of acute epoprostenol infusion (pulmonary edema) in a patient with pulmonary hypertension associated with limited scleroderma and discuss its management and potential etiology.|pulmonary edema|epoprostenol
A 14-year-old girl with newly diagnosed SLE developed a pruritic bullous eruption while on prednisone.|pruritic bullous eruption|prednisone
Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.|acute interstitial pneumonitis|Hydroxyurea
The clinical course suggests that the interstitial pneumonitis was induced by hydroxyurea.|interstitial pneumonitis|hydroxyurea
This is the first case of hydroxyurea-induced acute interstitial pneumonitis reported in the literature.|acute interstitial pneumonitis|hydroxyurea
Allergic and irritant contact dermatitis to calcipotriol.|irritant contact dermatitis|calcipotriol
Calcipotriol (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas allergic reactions are less common.|allergic reactions|Calcipotriol
Calcipotriol (Daivonex R; Leo Pharmaceuticals, Zurich, Switzerland) may cause irritation of the skin, whereas allergic reactions are less common.|irritation of the skin|Calcipotriol
The present observation suggests, that a batch of different testing doses, including lower testing doses may help to differentiate between an allergic type of contact dermatitis and an irritant type of reaction after treatment with calcipotriol.|irritant type of reaction|calcipotriol
Myotonia associated with sarcoidosis: marked exacerbation with pravastatin.|Myotonia|pravastatin
Pravastatin is associated with myotonia in animals.|myotonia|Pravastatin
This case suggests that sarcoidosis and pravastatin, two entities not frequently associated with myotonia, may interact in a synergistic manner to produce severe clinical myotonia in humans.|myotonia|pravastatin
Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and/or angioedema, or a systemic anaphylactoid reaction.|angioedema|aspirin
Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and/or angioedema, or a systemic anaphylactoid reaction.|systemic anaphylactoid reaction|aspirin
Hypersensitivity to aspirin can be manifested as acute asthma, urticaria and/or angioedema, or a systemic anaphylactoid reaction.|urticaria|aspirin
CONCLUSION: Fixed drug eruption is associated with many drugs but this is the first such report with omeprazole.|eruption|omeprazole
Fixed drug eruption in hands caused by omeprazole.|eruption|omeprazole
The objective of this report is to describe a case of fixed drug eruption that occurred during omeprazole treatment.|eruption|omeprazole
A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.|diffuse erythema|salazosulfapyridine
A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.|fever up to 39 degrees C|salazosulfapyridine
A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.|malaise|salazosulfapyridine
A 26-year-old Japanese man, who had been receiving medical attention for ulcerative colitis for one year, presented with diffuse erythema and pustules on his face and trunk, malaise, and fever up to 39 degrees C one day after the administration of salazosulfapyridine.|pustules|salazosulfapyridine
Acute generalized exanthematous pustulosis induced by salazosulfapyridine in a patient with ulcerative colitis.|Acute generalized exanthematous pustulosis|salazosulfapyridine
We report a case of acute generalized exanthematous pustulosis (AGEP) induced by salazosulfapyridine in a patient with ulcerative colitis.|acute generalized exanthematous pustulosis|salazosulfapyridine
CASE SUMMARY: A 39-year-old white Jewish schizophrenic man treated with olanzapine developed an elevated serum CK concentration with a peak concentration of 4000 IU/L (normal < 230).|elevated serum CK concentration|olanzapine
DISCUSSION: Olanzapine, like other atypical antipsychotic drugs, may cause muscle injury with concomitant elevations of serum CK of muscle origin.|muscle injury with concomitant elevations of serum CK|Olanzapine
Marked elevation of serum creatine kinase associated with olanzapine therapy.|elevation of serum creatine kinase|olanzapine
OBJECTIVE: To report a case of marked elevation of serum creatine kinase (CK) associated with olanzapine therapy.|elevation of serum creatine kinase|olanzapine
Diclofenac-associated hepatitis.|hepatitis|Diclofenac
This patient, who had a history of osteoarthritis, had severe hepatitis 5 weeks after being started on diclofenac for increasing pain in the joints.|hepatitis|diclofenac
2-CdA induces lymphocytopenia, which may explain the improvement in this patient's psoriasis.|lymphocytopenia|2-CdA
One case of priapism occurred during heparin therapy for a previous surgical operation to the knee is reported.|priapism|heparin
Priapism as a complication of heparin therapy.|Priapism|heparin
The association between heparin and priapism is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect.|abnormal platelet aggregation|heparin
The association between heparin and priapism is often recognized; abnormal platelet aggregation could play a role in the pathogenesis of this side effect.|priapism|heparin
It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.|agranulocytosis|clozapine
It carries a well-known risk of neutropenia and agranulocytosis, which necessitates the immediate discontinuation of clozapine.|neutropenia|clozapine
OBJECTIVE: We report a patient who developed neutropenia on clozapine, but behind the cell count decrease showed to be a diurnal variation of the white blood cells (WBC).|diurnal variation of the white blood cells|clozapine
Acute neutrophilic dermatosis induced by all-trans-retinoic acid treatment for acute promyelocytic leukemia.|Acute neutrophilic dermatosis|all-trans-retinoic acid
Findings on discontinuation and rechallenge supported the assumption that the hair loss was a side effect of the paroxetine.|hair loss|paroxetine
Hair loss associated with paroxetine treatment: a case report.|Hair loss|paroxetine
We report on a 37-year-old female who complained of moderate hair loss during paroxetine treatment.|hair loss|paroxetine
CONCLUSION: Patients with insulin allergy may not have complete resolution of their symptoms after standard desensitization, particularly those patients with concomitant protamine allergy.|protamine allergy|insulin
METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose.|angioedema|insulin
METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose.|angioedema|insulin
METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose.|severe urticaria|insulin
METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose.|severe urticaria|insulin
METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose.|wheezing|insulin
METHODS: The patient required insulin desensitization for severe urticaria, angioedema, and occasional wheezing resulting from her insulin dose.|wheezing|insulin
OBJECTIVE: The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control allergic symptoms in a patient allergic to both NPH and regular insulin.|allergic symptoms|insulin
OBJECTIVE: The purpose of this study was to determine whether desensitization to NPH insulin, as well as standard insulin desensitization, could control allergic symptoms in a patient allergic to both NPH and regular insulin.|allergic symptoms|NPH insulin
Patients receiving neutral protamine Hagedorn (NPH) insulin are at increased risk for the development of protamine hypersensitivity.|protamine hypersensitivity|neutral protamine Hagedorn (NPH) insulin
Protamine allergy as a complication of insulin hypersensitivity: A case report.|Protamine allergy|insulin
She continued to receive regular insulin 4 times per day over the following 3 years with only occasional hives.|hives|insulin
The patient had recurrence of urticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin.|angioedema|insulin
The patient had recurrence of urticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin.|angioedema|NPH
The patient had recurrence of urticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin.|urticaria|insulin
The patient had recurrence of urticaria and angioedema a year and a half later, at which point the NPH was stopped and she was desensitized to regular insulin.|urticaria|NPH
A 5-month-old infant became lethargic and poorly responsive after receiving 1 drop of brimonidine in each eye.|lethargic|brimonidine
A 5-month-old infant became lethargic and poorly responsive after receiving 1 drop of brimonidine in each eye.|poorly responsive|brimonidine
An 11-day-old infant became lethargic and apneic after a single drop of brimonidine.|apneic|brimonidine
An 11-day-old infant became lethargic and apneic after a single drop of brimonidine.|lethargic|brimonidine
Apparent central nervous system depression in infants after the use of topical brimonidine.|central nervous system depression|brimonidine
CONCLUSIONS: Topical brimonidine may be associated with central nervous system depression in infants.|central nervous system depression|brimonidine
PURPOSE: To report two cases in which topical brimonidine resulted in apparent central nervous system depression and unresponsiveness in an infant.|central nervous system depression|brimonidine
Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato-biliary enzymes and transient biliary stasis.|elevated hepato-biliary enzymes|ceftriaxone
Ceftriaxone was approved in 1997 for the treatment of otitis media despite previous studies that documented an association of ceftriaxone with elevated hepato-biliary enzymes and transient biliary stasis.|transient biliary stasis|ceftriaxone
Hepato-biliary abnormalities secondary to ceftriaxone use: a case report.|Hepato-biliary abnormalities|ceftriaxone
Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment.|Anterior lumbosacral radiculopathy|methotrexate
Reported are three children who developed progressive paraparesis after intrathecal methotrexate administration followed by complete or partial recovery.|progressive paraparesis|methotrexate
During the first days of arsenic trioxide treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes.|decrease in the D-dimers|arsenic trioxide
During the first days of arsenic trioxide treatment a rapid decrease in the D-dimers was seen (normal values reached until day 7), together with a slight decrease in peripheral blood leukocytes.|slight decrease in peripheral blood leukocytes|arsenic trioxide
A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.|chills|minocycline
A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.|fatigue|minocycline
A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.|fever|minocycline
A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.|generalized, pruritic, macular eruption|minocycline
A 22-year-old black man developed fever, chills, fatigue, night sweats, tender lymphadenopathy, and a generalized, pruritic, macular eruption 3 weeks after starting minocycline therapy for acne.|night sweats|minocycline
With the negative viral serologies, the clinical picture was most consistent with an infectious mononucleosis-like syndrome produced by the minocycline ingestion.|mononucleosis-like syndrome| minocycline
We conclude that the presence of this metabolic defect combined with topical 5-FU (a drug demonstrating a narrow therapeutic index) results in the unusual presentation of life-threatening toxicity after treatment with a topical drug.|life-threatening toxicity|5-FU
We now report the first known cancer patient who developed life-threatening complications after treatment with topical 5-FU and was shown subsequently to have profound DPD deficiency.|life-threatening complications|5-FU
An acute ischaemic event associated with the use of venlafaxine: a case report and proposed pathophysiological mechanisms.|acute ischaemic event|venlafaxine
The association of venlafaxine treatment with ischaemic events could be explained by its unique pharmacological and haemodynamic properties.|ischaemic events|venlafaxine
This is the first report of a possible association between an acute cardiovascular event and venlafaxine.|acute cardiovascular event|venlafaxine
We present a case of an elderly woman with a pre-existing history of ischaemic heart disease, who was treated with venlafaxine, and developed acute myocardial ischaemia within the first week of treatment.|acute myocardial ischaemia|venlafaxine
Apparent cyclophosphamide (cytoxan) embryopathy: a distinct phenotype?|embryopathy|cyclophosphamide
The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent CP embryopathy phenotype.|embryopathy|CP
The purpose of this report is to document a new case of in utero CP exposure with multiple congenital anomalies and to establish an apparent CP embryopathy phenotype.|multiple congenital anomalies|CP
The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|blepharophimosis|cyclosposphamide
The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|craniosynostosis|cyclosposphamide
The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|developmental delay|cyclosposphamide
The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|distal limb defects|cyclosposphamide
The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|flat nasal bridge|cyclosposphamide
The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|hypoplastic thumbs|cyclosposphamide
The reported cases of in utero exposure to cyclosposphamide shared the following manifestations with our patient: growth deficiency, developmental delay, craniosynostosis, blepharophimosis, flat nasal bridge, abnormal ears, and distal limb defects including hypoplastic thumbs and oligodactyly.|oligodactyly|cyclosposphamide
We conclude that (a) cyclophosphamide is a human teratogen, (b) a distinct phenotype exists, and (c) the safety of CP in pregnancy is in serious question.|human teratogen|cyclophosphamide
In all cases, seizures were controlled by withdrawal of phenytoin and reduction of drug levels.|seizures|phenytoin
Paradoxical seizures in phenytoin toxicity.|seizures|phenytoin
We present three patients with paradoxical seizures; their serum phenytoin levels were 43.5 mcg/mL, 46.5 mcg/mL and 38.3 mcg/mL.|seizures|phenytoin
CONCLUSIONS: This case suggests that losartan can induce late-onset angioedema in patients with normal renal function and that the reaction can recur after initial resolution of the symptoms.|angioedema|losartan
Losartan-induced angioedema.|angioedema|Losartan
OBJECTIVE: To report a case of angioedema associated with losartan administration.|angioedema|losartan
The incidence of angioedema secondary to losartan, an angiotensin II receptor antagonist, is unknown.|angioedema|losartan
We report the case of a female acromegalic patient in whom multiple hepatic adenomas appeared soon after danazol treatment for uterine fibromatosis.|hepatic adenomas|danazol
Heparin-induced thrombocytopenia is a rare and serious complication of anticoagulation therapy.|thrombocytopenia|Heparin
Pediatric heparin-induced thrombocytopenia: management with Danaparoid (orgaran).|thrombocytopenia|heparin
There remains a paucity of information pertaining to alternative anticoagulation strategies for use during cardiopulmonary bypass concomitant with heparin-induced thrombocytopenia, especially in children.|thrombocytopenia|heparin
We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).|hemorrhagic complications|heparin
We report the successful treatment of heparin-induced thrombocytopenia and subsequent hemorrhagic complications postoperatively in a 2-year-old child with Danaparoid (orgaran).|thrombocytopenia|heparin
Taxane-induced glaucoma.|glaucoma|Taxane
We report a case of glaucoma induced by doxetaxel therapy for metastatic breast cancer.|glaucoma|doxetaxel
Acute hyperphosphatemia caused by sodium phosphate enema in a patient with liver dysfunction and chronic renal failure.|hyperphosphatemia|sodium phosphate
We report a case of acute hyperphosphatemia secondary to rectal administration of sodium phosphate and sodium biphosphate (Fleet enema).|hyperphosphatemia|sodium biphosphate
We report a case of acute hyperphosphatemia secondary to rectal administration of sodium phosphate and sodium biphosphate (Fleet enema).|hyperphosphatemia|sodium phosphate
Prolongation of the QT interval and ventricular tachyarrhymias have been described in patients on amiodarone therapy.|Prolongation of the QT interval|amiodarone
Prolongation of the QT interval and ventricular tachyarrhymias have been described in patients on amiodarone therapy.|ventricular tachyarrhymias|amiodarone
We report a case of recurrent torsades de pointes following treatment with pentavalent antimonial drugs and amiodarone.|torsades de pointes|amiodarone
Emphasis is given to the differentiation of diphenylhydantoin induced gingival hyperplasia from the angiomatous enlargement of the gingiva before any treatment is planned.|gingival hyperplasia|diphenylhydantoin
A 66-year-old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D-penicillamine (D-Pen) treatment, although the leukopenia was not markedly severe.|anemia|D-Pen
A 66-year-old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D-penicillamine (D-Pen) treatment, although the leukopenia was not markedly severe.|anemia|D-penicillamine
A 66-year-old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D-penicillamine (D-Pen) treatment, although the leukopenia was not markedly severe.|thrombocytopenia|D-Pen
A 66-year-old Japanese woman with severe scleroderma developed anemia and thrombocytopenia due to D-penicillamine (D-Pen) treatment, although the leukopenia was not markedly severe.|thrombocytopenia|D-penicillamine
Cessation of D-Pen and the start of corticosteroid therapy were followed by recovery from bicytopenia.|bicytopenia|D-Pen
In vitro inhibition of hematopoiesis in a patient with systemic sclerosis treated with D-penicillamine.|inhibition of hematopoiesis|D-penicillamine
These findings suggest that bicytopenia in this patient was caused by D-Pen and may be due to different sensitivities in the hematopoietic lineage.|bicytopenia|D-Pen
A 48-year-old woman who was treated for thyrotoxicosis with methimazole developed agranulocytosis.|agranulocytosis|methimazole
Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case.|hypocalcemic tetany|alendronate sodium
Postoperative hypocalcemic tetany caused by fleet phospho-soda preparation in a patient taking alendronate sodium: report of a case.|hypocalcemic tetany|fleet phospho-soda
This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.|hypocalcemic tetany|alendronate
This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.|hypocalcemic tetany|Fleet Phospho-Soda
This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.|hypocalcemic tetany|Fosamax
This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.|hypophosphatemia|alendronate
This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.|hypophosphatemia|Fleet Phospho-Soda
This case report describes a patient who was previously prescribed alendronate (Fosamax) and presented with postoperative hypophosphatemia and hypocalcemic tetany after bowel preparation with Fleet Phospho-Soda.|hypophosphatemia|Fosamax
Described here are 2 patients who developed thrombotic microangiopathy of the kidneys after receiving high cumulative doses of the new anticancer drug gemcitabine.|thrombotic microangiopathy|gemcitabine
Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy.|renal failure|gemcitabine
Thrombotic microangiopathy with renal failure in two patients undergoing gemcitabine chemotherapy.|Thrombotic microangiopathy|gemcitabine
The first patient was a 61-year-old man with a 30-year history of fistulizing CD in whom B-cell non-Hodgkin's lymphoma was diagnosed 9 months after treatment with infliximab.|B-cell non-Hodgkin's lymphoma|infliximab
The relationship between infliximab treatment and lymphoma in Crohn's disease.|lymphoma|infliximab
The second is a 29-year-old man with CD in whom nodular sclerosing Hodgkin's lymphoma was diagnosed 3 weeks after infusion with infliximab.|nodular sclerosing Hodgkin's lymphoma|infliximab
We describe the clinical course of 2 patients with Crohn's disease (CD) in whom lymphoma was diagnosed after treatment with infliximab.|lymphoma|infliximab
Codeine intoxication in the neonate.|Codeine intoxication|Codeine
We report a case of codeine intoxication in the neonate, in which the drug was prescribed for cough control during an emergency department visit.|codeine intoxication|codeine
Hydroxyurea (HU) and sodium phenylbutyrate (SPB) have been shown to increase fetal hemoglobin (Hb F) levels in patients with thalassemia intermedia.|increase fetal hemoglobin|Hydroxyurea
Hydroxyurea (HU) and sodium phenylbutyrate (SPB) have been shown to increase fetal hemoglobin (Hb F) levels in patients with thalassemia intermedia.|increase fetal hemoglobin|sodium phenylbutyrate
Of the four patients who responded to HU with an increase in total Hb, all reported symptomatic improvement and three have not required further transfusions.|increase in total Hb|HU
Prolonged responses were achieved with low doses of HU (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or hepatic toxicity and no further increases in Hb.|hepatic toxicity|HU
Prolonged responses were achieved with low doses of HU (3-10 mg/kg/day) and higher doses were associated with mild reversible hematologic or hepatic toxicity and no further increases in Hb.|mild reversible hematologic|HU
Sodium phenylbutyrate was added to treatment with HU in two patients, but failed to produce an increase in total Hb despite increasing Hb F levels.|increasing Hb F|HU
Sodium phenylbutyrate was added to treatment with HU in two patients, but failed to produce an increase in total Hb despite increasing Hb F levels.|increasing Hb F|Sodium phenylbutyrate
We conclude that low-dose HU therapy in patients with thalassemia intermedia may increase total Hb levels sufficiently to eliminate the need for transfusions.|increase total Hb|HU
We describe the clinical response, as determined by increases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with SPB.|increases in total Hb|HU
We describe the clinical response, as determined by increases in total Hb and decreased transfusion needs, in five patients with thalassemia intermedia treated with HU alone or in combination with SPB.|increases in total Hb|SPB
A 36-y-o patient with schizophrenia, who had consumed gradually increasing quantities of oolong tea that eventually reached 15 L each day, became delirious and was admitted to a psychiatric hospital.|delirious|oolong tea
After abstinence from oolong tea his delirium resolved.|delirium|oolong tea
Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.|caffeine intoxication|caffeine
Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.|caffeine intoxication|oolong tea
Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.|rhabdomyolysis|caffeine
Severe rhabdomyolysis following massive ingestion of oolong tea: caffeine intoxication with coexisting hyponatremia.|rhabdomyolysis|oolong tea
The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.|delirium|caffeine
The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.|hyponatremia|caffeine
The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.|rhabdomyolysis|caffeine
The clinical course suggests that caffeine, which is present in oolong tea, was mainly responsible for the rhabdomyolysis as well as the delirium, although severe hyponatremia has been reported to cause rhabdomyolysis on rare occasions.|rhabdomyolysis|caffeine
The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.|rhabdomyolysis|caffeine
The possibility of severe rhabdomyolysis should be considered in a patient with water intoxication due to massive ingestion of caffeine-containing beverages.|water intoxication|caffeine
We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.|caffeine toxicity|caffeine
We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.|coexisting hyponatremia|caffeine
We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.|injured the muscle cells|caffeine
We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.|potassium depletion|caffeine
We hypothesize that caffeine toxicity injured the muscle cells, which were fragile due to the potassium depletion induced by the coexisting hyponatremia, to result in unusually severe rhabdomyolysis.|rhabdomyolysis|caffeine
After the addition of citalopram, a desmethylclomipramine plasma level increase and an 8-hydroacy-desmethylclomipramine plasma level decrease were observed.|8-hydroacy-desmethylclomipramine plasma level decrease|citalopram
After the addition of citalopram, a desmethylclomipramine plasma level increase and an 8-hydroacy-desmethylclomipramine plasma level decrease were observed.|desmethylclomipramine plasma level increase|citalopram
We report 3 cases of HIV-1 infected patients who experienced symptomatic angiolipomas shortly after starting antiretroviral therapy including the protease inhibitor indinavir.|angiolipomas|indinavir
Elevated serum triglycerides with clozapine resolved with risperidone in four patients.|Elevated serum triglycerides|clozapine
In two patients clozapine was reinstated after risperidone was discontinued; serum triglyceride levels increased.|serum triglyceride levels increased|clozapine
This increase when clozapine was switched to risperidone and vice versa is consistent with our previous report of elevated serum triglyceride levels in clozapine-treated patients.|elevated serum triglyceride levels|clozapine
Intravenous valproate associated with significant hypotension in the treatment of status epilepticus.|hypotension|valproate
To our knowledge, this is the first report of significant hypotension associated with intravenous valproate in the treatment of status epilepticus in the pediatric population.|hypotension|valproate
We report a case of severe hypotension associated with intravenous valproate used to treat status epilepticus in an 11-year-old girl.|hypotension|valproate
In both patients the rippling phenomena worsened with pyridostigmine treatment but markedly improved after immunosuppression with azathioprine.|rippling phenomena worsened|pyridostigmine
A diagnosis of masked theophylline poisoning should be considered in similar situations involving a rapid decrease of insulin requirements.|theophylline poisoning|theophylline
Salicylate intoxication was excluded, and theophylline was finally incriminated.|intoxication|theophylline
Theophylline intoxication mimicking diabetic ketoacidosis in a child.|Theophylline intoxication|Theophylline
This compound, used by adults in the child's home, had caused accidental theophylline poisoning, mimicking diabetic ketoacidosis.|theophylline poisoning|theophylline
Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature.|ifosfamide-induced encephalopathy|ifosfamide
Ten to 15% of patients treated with ifosfamide develop an encephalopathy.|encephalopathy|ifosfamide
We conclude that MB is an effective treatment for ifosfamide-induced encephalopathy.|ifosfamide-induced encephalopathy|ifosfamide
Portal vein thrombosis in a patient with severe haemophilia A and F V G1691A mutation during continuous infusion of F VIII after intramural jejunal bleeding--successful thrombolysis under heparin therapy.|Portal vein thrombosis|F VIII
We report on a 14-year-old boy with severe haemophilia A who developed a portal vein thrombosis during continuous infusion of F VIII.|portal vein thrombosis|F VIII
A 60-year-old woman with diabetes mellitus (type 2) developed an acute icteric hepatitis-like illness 6 weeks after the initiation of gliclazide therapy.|acute icteric hepatitis-like illness|gliclazide
Gliclazide-induced acute hepatitis.|acute hepatitis|Gliclazide
In conclusion, this case strongly suggests that gliclazide can induce acute icteric liver necro-inflammation which may be misdiagnosed clinically as acute viral hepatitis.|acute icteric liver necro-inflammation|gliclazide
We believe that this is the first description of acute hepatitis caused by an idiosyncratic adverse reaction to gliclazide or to one of its metabolites.|acute hepatitis|gliclazide
We describe the case of acute hepatitis induced by gliclazide, a second generation sulfonylurea.|acute hepatitis|gliclazide
Caution is, therefore, needed to prevent undesired accumulation of TCA that may lead to protracted Cushing's syndrome.|Cushing's syndrome|TCA
Cushing's syndrome persisted more than 6 months while TCA concentrations remained detectable for at least 80 days.|Cushing's syndrome|TCA
The presented patient was treated with 200 mg TCA and developed Cushing's syndrome 6 weeks later (cortisol and ACTH concentrations were below limits of detection, TCA concentrations were > 3 micrograms/l).|Cushing's syndrome|TCA
Both had impaired lung function and abnormal computed tomographic scans, and their condition improved when nitrofurantoin was withdrawn and corticosteroid treatment commenced.|abnormal computed tomographic scans|nitrofurantoin
Both had impaired lung function and abnormal computed tomographic scans, and their condition improved when nitrofurantoin was withdrawn and corticosteroid treatment commenced.|impaired lung function|nitrofurantoin
Bronchiolitis obliterans organising pneumonia associated with the use of nitrofurantoin.|Bronchiolitis obliterans organising pneumonia|nitrofurantoin
The case histories are presented of two patients who developed lung disease associated with the use of nitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury.|BOOP|nitrofurantoin
The case histories are presented of two patients who developed lung disease associated with the use of nitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury.|bronchiolitis obliterans organising pneumonia|nitrofurantoin
The case histories are presented of two patients who developed lung disease associated with the use of nitrofurantoin with histological features of bronchiolitis obliterans organising pneumonia (BOOP), a rare but recognised form of drug induced injury.|lung disease|nitrofurantoin
The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of nitrofurantoin induced BOOP.|fatal outcome|nitrofurantoin
The favourable outcome in these two patients contrasts with the fatal outcome of the two other reported cases of nitrofurantoin induced BOOP.|nitrofurantoin induced BOOP|nitrofurantoin
The spectrum of nitrofurantoin lung injury continues to widen.|lung injury|nitrofurantoin
The two middle aged women presented with respiratory symptoms after prolonged treatment with nitrofurantoin.|respiratory symptoms|nitrofurantoin
We suggest that the previous classification of nitrofurantoin induced lung injury into "acute" and "chronic" injury is an oversimplification in view of the wide variety of pathological entities that have subsequently emerged.|nitrofurantoin induced lung injury|nitrofurantoin
Intravenous administration of levodopa ameliorated a refractory akathisia case induced by interferon-alpha.|akathisia|interferon-alpha
The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.|akathisia|interferon-alpha
The present report illustrates a rare case of refractory akathisia after interferon-alpha treatment and also that levodopa treatment would be theoretically and practically useful in reducing the neurotoxicity associated with interferon-alpha.|neurotoxicity|interferon-alpha
Acute erythroid leukemia after cyclophosphamide therapy for multiple myeloma: report of two cases.|Acute erythroid leukemia|cyclophosphamide
The development of erythroid leukemia plus carcinoma in these two men suggests mutagenic change secondary to cyclophosphamide therapy.|carcinoma|cyclophosphamide
Scleroderma-like reaction induced by uracil-tegafur (UFT), a second-generation anticancer agent.|Scleroderma-like reaction|UFT
Scleroderma-like reaction induced by uracil-tegafur (UFT), a second-generation anticancer agent.|Scleroderma-like reaction|uracil-tegafur
This is the first report of UFT-induced scleroderma-like reaction.|UFT-induced scleroderma-like reaction|UFT
We report a case of a scleroderma-like reaction induced by long-term administration of UFT.|scleroderma-like reaction|UFT
Central nervous system manifestations of an ibuprofen overdose reversed by naloxone.|Central nervous system manifestations|ibuprofen
Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.|dizziness|Ibuprofen
Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.|GI upset|Ibuprofen
Ibuprofen overdose is usually characterized by GI upset, dizziness, and mild sedation.|mild sedation|Ibuprofen
Presently, treatment of acute ibuprofen intoxication with complications requires supportive therapy until the symptoms resolve over 24 to 48 hours.|ibuprofen intoxication|ibuprofen
We report the case of an 11-month-old female infant with a depressed level of consciousness after ingestion of ibuprofen whose mental status markedly improved with administration of naloxone.|depressed level of consciousness|ibuprofen
Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome.|acute respiratory failure|Flecainide
Flecainide-associated pneumonitis with acute respiratory failure in a patient with the LEOPARD syndrome.|pneumonitis|Flecainide
Flecainide is a rare cause of hypersensitivity pneumonitis, and few cases have been reported.|hypersensitivity pneumonitis|Flecainide
We describe a case of interstitial hypoxaemiant pneumonitis probably related to flecainide in a patient with the LEOPARD syndrome, a rare congenital disorder.|interstitial hypoxaemiant pneumonitis|flecainide
Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.|Sagittal sinus thrombosis|L-asparaginase
Sagittal sinus thrombosis associated with transient free protein S deficiency after L-asparaginase treatment: case report and review of the literature.|transient free protein S deficiency|L-asparaginase
We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.|seizure|L-asparaginase
We report the case of an adult patient with acute lymphoblastic leukemia who presented with repeated transient ischemic attacks followed by a seizure during consolidation treatment with L-asparaginase.|transient ischemic attacks|L-asparaginase
We report on a young adolescent with benign intracranial hypertension which we attribute to the use of minocycline for acne.|benign intracranial hypertension|minocycline
We report 2 patients who developed polyarteritis nodosa following vaccination against hepatitis B.|polyarteritis nodosa|vaccination against hepatitis B
In this case, it was suspected that a combination of cigarette smoking, pulmonary fibrosis, and low-dose methotrexate therapy might have promoted the development of lung cancer.|lung cancer|methotrexate
This case report illustrates the use of continuous high-dose intracoronary nitroglycerin infusion through a 6 French coronary guiding catheter in the treatment of a patient with cocaine-induced refractory coronary vasospasm.|refractory coronary vasospasm|cocaine
However, as illustrated by these and other cases reported to date, the onset of troglitazone-induced liver injury is insidious and temporally variable.|liver injury|troglitazone
It remains to be seen whether the hepatotoxicity associated with troglitazone is a drug-class effect or specific to troglitazone.|hepatotoxicity|troglitazone
It remains to be seen whether the hepatotoxicity associated with troglitazone is a drug-class effect or specific to troglitazone.|hepatotoxicity|troglitazone
Other thiazolidinediones currently in clinical trials may be able to provide the therapeutic benefits of troglitazone without significant hepatotoxicity.|hepatotoxicity|troglitazone
The three reported cases demonstrate that troglitazone is an idiosyncratic hepatotoxin that can lead to irreversible liver injury.|irreversible liver injury|troglitazone
Troglitazone-induced fulminant hepatic failure.|fulminant hepatic failure|Troglitazone
Nitrofurantoin-induced lung disease: two cases demonstrating resolution of apparently irreversible CT abnormalities.|lung disease|Nitrofurantoin
We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.|distortion of the lung parenchyma|nitrofurantoin
We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.|fibrosis|nitrofurantoin
We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.|pulmonary toxicity|nitrofurantoin
We present two cases of nitrofurantoin-induced pulmonary toxicity in which the initial HRCT showed a widespread reticular pattern and associated distortion of the lung parenchyma, thought to represent established fibrosis.|widespread reticular pattern|nitrofurantoin
Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency.|death|Fluoxetine
The medical examiner's report indicated death caused by fluoxetine toxicity.|death|fluoxetine
The medical examiner's report indicated death caused by fluoxetine toxicity.|fluoxetine toxicity|fluoxetine
This is the first report of a fluoxetine-related death in a child with a confirmed genetic polymorphism of the CYP2D6 gene that results in impaired drug metabolism.|death|fluoxetine
A 50-year-old woman with a history of migraine without aura, predominantly occurring around her menstrual periods, developed a spinal cord lesion following the use of zolmitriptan.|spinal cord lesion|zolmitriptan
Spinal cord infarction during use of zolmitriptan: a case report.|Spinal cord infarction|zolmitriptan
The temporal relationship suggests that the spinal cord infarction may be related to the use of zolmitriptan.|spinal cord infarction|zolmitriptan
CASE SUMMARY: A 10-year-old white girl with bilateral optic glioma developed a hypersensitivity reaction to carboplatin after nine courses.|hypersensitivity|carboplatin
This regimen could prove useful for other patients who develop hypersensitivity reactions to carboplatin and allow therapy to continue.|hypersensitivity|carboplatin
Perinatal vasoconstrictive renal insufficiency associated with maternal nimesulide use.|renal insufficiency|nimesulide
This is the first report of an adverse effect of fetal renal circulation by maternal ingestion of nimesulide.|adverse effect of fetal renal circulation|nimesulide
Although the t-AML developed following oral etoposide therapy, the child had previously received high-dose, multiagent chemotherapy, and rearrangement of the MLL gene was not demonstrated.|t-AML|etoposide
Secondary leukemia in a child with neuroblastoma while on oral etoposide: what is the cause?|Secondary leukemia|etoposide
The authors present a case of t-AML that developed in a child with metastatic neuroblastoma 18 months after he received oral etoposide, given for palliation purpose.|t-AML|etoposide
BACKGROUND: Cyanamide, an aversive agent widely used in Japan, is known to induce various degrees of hepatic lesion with ground-glass inclusion bodies.|hepatic lesion with ground-glass inclusion bodies|Cyanamide
Case 2: A 43-year-old male alcoholic remained completely abstinent with cyanamide treatment for 5 years and complained of general fatigue.|general fatigue|cyanamide
Case 3: A 29-year-old female alcoholic complained of general fatigue and a slight fever after 1.5 years of abstinence with cyanamide treatment.|fatigue|cyanamide
Case 3: A 29-year-old female alcoholic complained of general fatigue and a slight fever after 1.5 years of abstinence with cyanamide treatment.|fever|cyanamide
Case 4: A 61-year-old male alcoholic who remained completely abstinent while taking cyanamide for 3 years showed slight elevation of serum transaminases.|elevation of serum transaminases|cyanamide
CONCLUSION: In some abstainers who take cyanamide for several years, thin septum-like liver fibrosis progresses along with the emergence of ground-glass hepatocytes.|ground-glass hepatocytes|cyanamide
CONCLUSION: In some abstainers who take cyanamide for several years, thin septum-like liver fibrosis progresses along with the emergence of ground-glass hepatocytes.|septum-like liver fibrosis|cyanamide
Cyanamide-induced liver dysfunction after abstinence in alcoholics: a long-term follow-up study on four cases.|liver dysfunction|Cyanamide
When cyanamide-treated alcoholics relapse into drinking, more severe inflammation develops in the liver.|inflammation|cyanamide
A patient with an allergy to a macrolide antibiotic was given tacrolimus and developed a sudden cutaneous reaction.|sudden cutaneous reaction|tacrolimus
A 77-year-old woman with no history of epilepsy presented a probable nonconvulsive status epilepticus while receiving continuous intravenous morphine for back pain relating to vertebral metastasis of a malignant lymphoma.|nonconvulsive status epilepticus|morphine
A generalized tonic-clonic seizure occurred a few minutes after injection of the morphine antagonist naloxone.|generalized tonic-clonic seizure|naloxone
Nonconvulsive status epilepticus: the role of morphine and its antagonist.|Nonconvulsive status epilepticus|morphine
Spontaneous bacterial peritonitis induced by intraarterial vasopressin therapy.|bacterial peritonitis|vasopressin
Although the literature on the use of risperidone in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms (EPS).|EPS|risperidone
Although the literature on the use of risperidone in elderly patients with dementia consists largely of uncontrolled trials, case reports, and chart reviews, it appears that this agent is effective for managing agitation in this population and does so with a low frequency of extrapyramidal symptoms (EPS).|extrapyramidal symptoms|risperidone
Three months following splenectomy, multiple abscesses occurred in the muscles of both thighs while the patient was receiving the third course of the CHOP regimen.|multiple abscesses|CHOP
After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.|anti-native DNA antibodies|ethambutol
After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.|hepatitis|ethambutol
After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.|polyarthritis|ethambutol
After seven months' continuous treatment for suspected tuberculosis with rifampicin and ethambutol a nine-year-old boy developed polyarthritis, rash and hepatitis in association with anti-native DNA antibodies and positive antinuclear factor.|rash|ethambutol
Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.|anti-native DNA antibodies|ethambutol
Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.|anti-native DNA antibodies|rifampicin
Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.|hepatitis|ethambutol
Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.|hepatitis|rifampicin
Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.|Polyarthritis|ethambutol
Polyarthritis, hepatitis and anti-native DNA antibodies after treatment with ethambutol and rifampicin.|Polyarthritis|rifampicin
A case of normotensive scleroderma renal crisis after high-dose methylprednisolone treatment.|normotensive scleroderma renal crisis|methylprednisolone
HUS has been reported after several anticancer chemotherapies and most often after mitomycin C-based chemotherapy regimens.|HUS|mitomycin C
Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.|Severe hemolytic uremic syndrome|carboplatin
Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.|Severe hemolytic uremic syndrome|gemcitabine
We present a case of HUS in an advanced ovarian cancer patient treated with carboplatin and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up.|HUS|carboplatin
We present a case of HUS in an advanced ovarian cancer patient treated with carboplatin and gemcitabine, and described its favorable outcome after chemotherapy interruption and supportive care with a 1 year follow-up.|HUS|gemcitabine
An evaluation of ovarian structure and function should be considered in women of reproductive age being treated with valproate for epilepsy, especially if they develop menstrual cycle disturbances during treatment.|menstrual cycle disturbances|valproate
BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy.|hyperandrogenism|sodium valproate
BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy.|menstrual disorders|sodium valproate
BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy.|polycystic ovaries|sodium valproate
BACKGROUND: Reproductive endocrine disorders characterized by menstrual disorders, polycystic ovaries, and hyperandrogenism seem to be common among women treated with sodium valproate for epilepsy.|Reproductive endocrine disorders|sodium valproate
CONCLUSIONS: The 3 cases presented here illustrate the development of reproductive endocrine disorders after the initiation of valproate therapy in women with epilepsy.|reproductive endocrine disorders|valproate
OBJECTIVE: To describe the development of valproate-related reproductive endocrine disorders in women with epilepsy.|reproductive endocrine disorders|valproate
PATIENTS: Three patients developed a reproductive endocrine disorder during treatment with valproate.|reproductive endocrine disorder|valproate
RESULTS: Replacing valproate with lamotrigine resulted in a decrease in serum testosterone concentrations in all 3 women.|serum testosterone|valproate
The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication.|amenorrhea|valproate
The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication.|gained weight|valproate
The polycystic changes disappeared from the ovaries in 2 of the women after valproate therapy was discontinued, and the 2 women who had gained weight and developed amenorrhea while being treated with valproate lost weight and resumed menstruating after the change in medication.|polycystic changes|valproate
However, recurrent staphylococcus aureus sepsis developed during CyA therapy.|staphylococcus aureus sepsis|CyA
Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis.|lethal|cyclosporine
Recurrent septicemia with lethal outcome during and after cyclosporine therapy in severe ulcerative colitis.|septicemia|cyclosporine
A 60 year-old woman with chronic renal failure developed acute proximal muscle weakness after receiving a regular dosage of colchicine.|proximal muscle weakness|colchicine
Colchicine-induced myopathy in renal failure.|myopathy|Colchicine
Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of colchicine-induced myopathy.|myopathy|colchicine
Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of colchicine-induced myopathy.|vacuolated fibers|colchicine
Muscle biopsy revealed variation in muscle fiber size and few vacuolated fibers which were features of colchicine-induced myopathy.|variation in muscle fiber size|colchicine
A third patient experienced disabling neurotoxicity in the extremity of a prior ulnar nerve and tendon transposition after receiving paclitaxel.|disabling neurotoxicity|paclitaxel
Phantom limb pain as a manifestation of paclitaxel neurotoxicity.|neurotoxicity|paclitaxel
Phantom limb pain as a manifestation of paclitaxel neurotoxicity.|Phantom limb pain|paclitaxel
Physicians should be aware that PLP can occur after initiation of paclitaxel.|PLP|paclitaxel
We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.|phantom limb pain|paclitaxel
We describe 2 patients with prior amputation who experienced phantom limb pain (PLP) after receiving paclitaxel therapy.|PLP|paclitaxel
Skin manifestations of a case of phenylbutazone-induced serum sickness-like reactions.|serum sickness-like reactions|phenylbutazone
Skin manifestations of a case of phenylbutazone-induced serum sickness-like reactions.|Skin manifestations|phenylbutazone
Our experience supports hemodialysis for ESRF patients with atenolol toxicity.|atenolol toxicity|atenolol
Allergic reaction to gemfibrozil manifesting as eosinophilic gastroenteritis.|eosinophilic gastroenteritis|gemfibrozil
We describe a case of EGE manifested as an allergy to gemfibrozil.|EGE|gemfibrozil
This is the second report of lactic acidosis in a patient on stavudine and lamivudine.|lactic acidosis|lamivudine
This is the second report of lactic acidosis in a patient on stavudine and lamivudine.|lactic acidosis|stavudine
We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.|lactic acidosis|lamivudine
We present an AIDS patient with severe and prolonged lactic acidosis on stavudine and lamivudine.|lactic acidosis|stavudine
Ataxia caused by propafenone has been reported to the pharmaceutical companies and drug monitoring agencies, but has not been well described or emphasized in the medical literature.|Ataxia|propafenone
A wide variety of adverse central nervous system effects have been reported in association with propafenone; dizziness is the most common.|adverse central nervous system effects|propafenone
A wide variety of adverse central nervous system effects have been reported in association with propafenone; dizziness is the most common.|dizziness|propafenone
Propafenone-induced ataxia: report of three cases.|ataxia|Propafenone
We describe 3 elderly patients with moderate to severe ataxia that occurred while they were taking propafenone.|ataxia|propafenone
A 74-year-old man received oral administration of pilsicainide, a pure sodium channel blocker with slow recovery kinetics, to convert paroxysmal atrial fibrillation to sinus rhythm and developed loss of consciousness two days later.|loss of consciousness|pilsicainide
When pilsicainide is prescribed in patients with coronary artery disease or renal dysfunction, close attention must be paid to avoid life-threatening arrhythmias due to high plasma concentrations of the drug.|life-threatening arrhythmias|pilsicainide
The cases are important in documenting that drug-induced dystonias do occur in patients with dementia, that risperidone appears to have contributed to dystonia among elderly patients, and that the categorization of dystonic reactions needs further clarification.|dystonia|risperidone
Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients.|non-convulsive status epilepticus|tiagabine
The events of non-convulsive status epilepticus subsided following reduction in tiagabine dosages.|non-convulsive status epilepticus|tiagabine
This is the first report of non-convulsive status epilepticus provoked by tiagabine in adolescent patients.|non-convulsive status epilepticus|tiagabine
There have been many reports of probable lithium-induced organic brain syndromes occurring when serum lithium levels are within or close to the therapeutic range.|organic brain syndromes|lithium
When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium neurotoxicity.|intense anxiety|lithium
When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium neurotoxicity.|neurotoxicity|lithium
When the acute manic state is characterized by marked psychotic symptoms and intense anxiety, it may be associated with increased vulnerability to the development of severe lithium neurotoxicity.|psychotic symptoms|lithium
Protease inhibitor-induced carbamazepine toxicity.|carbamazepine toxicity|carbamazepine
Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity.|carbamazepine toxicity|carbamazepine
Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity.|carbamazepine toxicity|ritonavir
Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity.|carbamazepine toxicity|saquinavir
Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity.|progressive ataxia|carbamazepine
Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity.|progressive ataxia|ritonavir
Protease inhibitors (ritonavir and saquinavir) were added to the treatment and the patient developed progressive ataxia related to carbamazepine toxicity.|progressive ataxia|saquinavir
Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity.|clinical toxicity|Ritonavir
Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity.|diminishing carbamazepine metabolism|Ritonavir
Ritonavir acted as a CYP3A4 inhibitor, diminishing carbamazepine metabolism and provoking an increase in serum levels and clinical toxicity.|increase in serum levels|Ritonavir
The patient was diagnosed with carbamazepine toxicity related to the introduction of ritonavir.|carbamazepine toxicity|carbamazepine
The patient was diagnosed with carbamazepine toxicity related to the introduction of ritonavir.|carbamazepine toxicity|ritonavir
Anaphylaxis to calcitonin.|Anaphylaxis|calcitonin
CONCLUSION: We have introduced a case of anaphylaxis by calcitonin that suggest an IgE mediated hypersensitivity reaction.|anaphylaxis |calcitonin
The intramuscular challenge test with 25 UI of Miacalcic was positive with an immediate anaphylactic reaction.|anaphylactic reaction|Miacalcic
We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).|conjunctivitis|calcitonin
We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).|conjunctivitis|Calsynar
We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).|perspiration|calcitonin
We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).|perspiration|Calsynar
We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).|rhinitis|calcitonin
We introduce a case of a sixty years old woman with several previous episodes of rhinitis, conjunctivitis and perspiration immediately after the administration of salmon calcitonin with nasal spray or intramuscular administration (Calsynar).|rhinitis|Calsynar
Minocycline as a cause of drug-induced autoimmune hepatitis.|autoimmune hepatitis|Minocycline
Minocycline-induced autoimmune hepatitis is usually identical to sporadic autoimmune hepatitis.|autoimmune hepatitis|Minocycline
We describe the clinical and liver biopsy morphologic features for 4 patients with minocycline-induced autoimmune hepatitis (group 1).|autoimmune hepatitis|minocycline
L-asparaginase-provoked seizures as singular expression of central nervous toxicity.|central nervous toxicity|L-asparaginase
L-asparaginase-provoked seizures as singular expression of central nervous toxicity.|seizures|L-asparaginase
Patients treated with L-asparaginase may present with hemorrhagic and thrombotic cerebrovascular events.|hemorrhagic|L-asparaginase
Patients treated with L-asparaginase may present with hemorrhagic and thrombotic cerebrovascular events.|thrombotic cerebrovascular events|L-asparaginase
We report a case of seizure associated with L-asparaginase therapy but no evidence of hemorrhagic or thrombotic cerebrovascular events.|seizure|L-asparaginase
Eighty-two patients with various malignancies who received imipenem/cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified.|neutropenic fever|cilastatin
Eighty-two patients with various malignancies who received imipenem/cilastatin 143 times for neutropenic fever between March 1994 and October 1999 in Department of Pediatric Oncology, Gazi University, were identified.|neutropenic fever|imipenem
Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.|seizures|cilastatin
Incidence of seizures in pediatric cancer patients treated with imipenem/cilastatin.|seizures|imipenem
Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects.|Proconvulsive|cilastatin
Proconvulsive tendency of imipenem/cilastatin is one of its well-known side effects.|Proconvulsive|imipenem
Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.|convulsions|cilastatin
Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.|convulsions|imipenem
Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.|seizure|cilastatin
Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.|seizure|imipenem
Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.|seizure|cilastatin
Three of these patients had convulsions attributed to imipenem/cilastatin; 3.6% of the patients had seizure, or 2% of imipenem/cilastatin administrations was followed by a seizure attack.|seizure|imipenem
Gabapentin-induced mood changes with hypomanic features in adults.|hypomanic|Gabapentin
Gabapentin-induced mood changes with hypomanic features in adults.|mood changes|Gabapentin
We report two adults who received gabapentin (GBP) and subsequently developed behavioural side effects.|behavioural side effects|gabapentin
We report two adults who received gabapentin (GBP) and subsequently developed behavioural side effects.|behavioural side effects|GBP
Acute pancreatitis in a child with idiopathic ulcerative colitis on long-term 5-aminosalicylic acid therapy.|Acute pancreatitis|5-aminosalicylic acid
We describe a 10-year-old boy with ulcerative colitis who developed acute pancreatitis while on long-term treatment with 5-aminosalicylic acid.|acute pancreatitis|5-aminosalicylic acid
CONCLUSION: Marked visual field constriction appears to be associated with vigabatrin therapy.|visual field constriction|vigabatrin
Electro-oculography, electroretinography, visual evoked potentials, and multifocal electroretinography in patients with vigabatrin-attributed visual field constriction.|visual field constriction|vigabatrin
PURPOSE: Symptomatic visual field constriction thought to be associated with vigabatrin has been reported.|visual field constriction|vigabatrin
The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin-attributed visual field loss, three of whom were reported previously.|visual field loss|vigabatrin
The field defects and some electrophysiological abnormalities persist when vigabatrin therapy is withdrawn.|field defects|vigabatrin
Depressive symptoms disappeared after interferon therapy was stopped.|Depressive symptoms|interferon
Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects.|psychiatric side effects|IFN-alpha
Treatment of chronic hepatitis C with interferon alpha (IFN-alpha) is relatively contraindicated in patients with psychiatric disorders because of possible severe psychiatric side effects.|psychiatric side effects|interferon alpha
While for ribavirin antidepressant effects are not known, we suppose that antidepressants may prevent changes in serotonergic or noradrenergic neurotransmission caused by IFN-alpha.|changes in serotonergic or noradrenergic neurotransmission|IFN-alpha
Intensive high-flux hemodiafiltration is often used in the management of vancomycin toxicity.|vancomycin toxicity|vancomycin
Management of hypophosphatemia induced by high-flux hemodiafiltration for the treatment of vancomycin toxicity: intravenous phosphorus therapy versus use of a phosphorus-enriched dialysate.|vancomycin toxicity|vancomycin
We describe 2 children with cerebral palsy who suffered significant morbidity immediately after treatment with hyperbaric oxygen.|morbidity|hyperbaric oxygen
A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.|brown discolouration of the fingernails|0.1% tretinoin cream
A 33-year-old male presented with brown discolouration of the fingernails following the application of 4% hydroquinone in sorbolene cream and 0.1% tretinoin cream to the face intermittently for 9 months.|brown discolouration of the fingernails|4% hydroquinone in sorbolene cream
Nail staining from hydroquinone cream.|Nail staining|hydroquinone
Gangrene of the fingertips after bleomycin and methotrexate.|Gangrene|bleomycin
Gangrene of the fingertips after bleomycin and methotrexate.|Gangrene|methotrexate
This supports the well-reported potential of bleomycin to trigger acral vascular toxicity.|acral vascular toxicity|bleomycin
We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.|acute digital ischemia|bleomycin
We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.|acute digital ischemia|methotrexate
We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.|gangrene|bleomycin
We describe a 57-year-old man with acral erythrocyanosis progressing to acute digital ischemia and gangrene that developed after combined chemotherapy (bleomycin and methotrexate) used to treat a metastatic squamous cell carcinoma of the hypopharynx.|gangrene|methotrexate
Diarrhea-associated over-anticoagulation in a patient taking warfarin: therapeutic role of cholestyramine.|Diarrhea-associated over-anticoagulation|warfarin
We present a case of significant over-anticoagulation temporally associated with a bout of protracted diarrhea in a patient on warfarin therapy.|diarrhea|warfarin
We present a case of significant over-anticoagulation temporally associated with a bout of protracted diarrhea in a patient on warfarin therapy.|over-anticoagulation|warfarin
MI related to the use of activated and non-activated PCCs predominantly affects young patients who often have no preceding history of, or risk factors for, MI and tends to be associated with large cumulative doses of concentrate.|MI|PCCs
Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors.|myocardial infarction|prothrombin complex concentrate
We have safely used recombinant factor VIIa to treat bleeding in the immediate and long-term period following PCC-related MI.|MI|PCC
Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.|thrombocytopenia|quinine
Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.|thrombocytopenia|quinine
Even after a strict warning, he took another quinine tablet that evening, which triggered his fifth episode of severe thrombocytopenia, and confirmed the etiology of quinine-induced thrombocytopenia.|thrombocytopenia|quinine
Occult quinine-induced thrombocytopenia.|thrombocytopenia|quinine
Only after three subsequent episodes of severe, symptomatic thrombocytopenia over the next four weeks did he say, upon repeat questioning, that he had continued to take quinine for night leg cramps.|thrombocytopenia|quinine
An 8-year-old child with familial Mediterranean fever exhibited signs of colchicine intoxication while receiving prophylactic doses of the drug.|colchicine intoxication|colchicine
CONCLUSION: To the best of our knowledge, this is the first time colchicine intoxication in this age group has been described in the English literature.|colchicine intoxication|colchicine
Near fatal acute colchicine intoxication in a child.|colchicine intoxication|colchicine
Near fatal acute colchicine intoxication in a child.|Near fatal|colchicine
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.|Acute myeloid leukemia|fludarabine
Acute myeloid leukemia and lung cancer occurring in a chronic lymphocytic leukemia patient treated with fludarabine and autologous peripheral blood stem-cell transplantation.|lung cancer|fludarabine
We describe the exceptional development of AML and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after fludarabine treatment followed by autologous peripheral blood stem-cell transplantation.|AML|fludarabine
We describe the exceptional development of AML and lung cancer in a patient with previously diagnosed CLL in minimal residual disease status after fludarabine treatment followed by autologous peripheral blood stem-cell transplantation.|lung cancer|fludarabine
In 2 of the 3 cases the patients were also taking lithium carbonate and beta-blockers, both of which could have contributed to the incontinence.|incontinence|lithium carbonate
In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.|incontinence|paroxetine
In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.|incontinence|sertraline
In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline, as well as a third who developed this side effect on venlafaxine.|incontinence|venlafaxine
This concerns 2 male patients who experienced incontinence while taking venlafaxine.|incontinence|venlafaxine
Case studies in heparin-induced thrombocytopenia.|thrombocytopenia|heparin
Major points illustrated are, (1) occurrence of HIT with any dose or form of heparin; (2) misperceptions on the diagnostic criteria; (3) correct (thrombin inhibitors) and incorrect (platelet transfusions and warfarin) management; (4) influence of management strategy on clinical outcomes; (5) severity of the syndrome; and (6) potential for both anamnestic response to heparin and disappearance of HIT antibodies over time.|HIT|heparin
Type II heparin-induced thrombocytopenia (HIT) is an immunological disorder characterized by antibodies to heparin-platelet factor 4 complexes and a high risk of thrombotic complications.|thrombocytopenia|heparin
After several unrevealing medical work-ups, he was found to have a high blood lead level (122 microg/dL); he has a history of scraping and sanding lead paint without adequate protective measures.|high blood lead level|lead
It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.|hypertension|lead
It also highlights a current major etiologic question, that is, whether and to what degree lead exposure contributes to the development of hypertension, and raises the issue of whether lead-induced hypertension constitutes a subset of hypertension that is especially amenable to therapy with dietary calcium.|lead-induced hypertension|lead
Poorly controlled hypertension in a painter with chronic lead toxicity.|lead toxicity|lead
This case demonstrates an occupational activity (construction) that has now become the dominant source of lead exposure for U.S. adults, the importance of a good occupational history to suspecting and making a diagnosis, the possible outcomes of chronic lead toxicity, and the importance of preventing further exposure and using proper methods to treat acute toxicity.|lead toxicity|lead
Severe rash, including the Stevens-Johnson syndrome (SJS), is the major toxicity of nevirapine and is described in the package labeling with a prominent, boxed warning.|Severe rash|nevirapine
Severe rash, including the Stevens-Johnson syndrome (SJS), is the major toxicity of nevirapine and is described in the package labeling with a prominent, boxed warning.|SJS|nevirapine
Severe rash, including the Stevens-Johnson syndrome (SJS), is the major toxicity of nevirapine and is described in the package labeling with a prominent, boxed warning.|Stevens-Johnson syndrome|nevirapine
Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine.|Stevens-Johnson syndrome|nevirapine
Though physicians treating large populations of patients with HIV are well aware of this complication, only one other report of nevirapine-associated SJS has been documented in the dermatology literature.|SJS|nevirapine
We describe 2 cases of SJS related to nevirapine use and review the literature on this newly recognized association.|SJS|nevirapine
Oral intake and acarbose were withheld and the ileus spontaneously resolved after 2 days.|ileus|acarbose
There is evidence that the angiotensin II receptor antagonist, losartan, increases urate excretion by reducing reabsorption of urate in the renal proximal tubule.|increases urate excretion|losartan
Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.|Atrial fibrillation|etanercept
Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.|Atrial fibrillation|methotrexate
A review of the literature revealed two other cases of hepatic angiosarcoma in patients after long-term cyclophosphamide treatment.|hepatic angiosarcoma|cyclophosphamide
Hepatic angiosarcoma occurring after cyclophosphamide therapy: case report and review of the literature.|Hepatic angiosarcoma|cyclophosphamide
We propose that cyclophosphamide be added to the list of exposures potentially associated with hepatic angiosarcoma.|hepatic angiosarcoma|cyclophosphamide
ARA-C is frequently associated with dermatologic toxicity, but this is only the second case of toxic epidermal necrolysis described in connection with this drug.|dermatologic toxicity|ARA-C
ARA-C is frequently associated with dermatologic toxicity, but this is only the second case of toxic epidermal necrolysis described in connection with this drug.|toxic epidermal necrolysis|ARA-C
On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day.|bullous lesions on the hands and soles that disseminated, evolving to necrosis|ARA-C
On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day.|death|ARA-C
On the fifth day after administration of a high dose of ARA-C (2 g/m2 intravenously every 12 hours), she developed bullous lesions on the hands and soles that disseminated, evolving to necrosis, sepsis, and death on the 22nd day.|sepsis|ARA-C
Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside.|Toxic epidermal necrolysis|cytosine arabinoside
We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a high dose of cytosine arabinoside (ARA-C).|TEN|ARA-C
We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a high dose of cytosine arabinoside (ARA-C).|TEN|cytosine arabinoside
We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a high dose of cytosine arabinoside (ARA-C).|toxic epidermal necrolysis|ARA-C
We report a fatal case of toxic epidermal necrolysis (TEN) resulting from a high dose of cytosine arabinoside (ARA-C).|toxic epidermal necrolysis|cytosine arabinoside
Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS.|obsessive-compulsive symptoms|Quetiapine
Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS.|OCS|Quetiapine
Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS.|OCS|Quetiapine
The first known report of quetiapine exacerbating OCS in a 43-year-old man with obsessive-compulsive disorder (OCD), trichotillomania, delusional disorder and bipolar II disorder is presented.|exacerbating OCS|quetiapine
He was diagnosed with possible serotonin syndrome; his symptoms resolved after clomipramine was stopped but before clozapine was restarted eight days later.|serotonin syndrome|clomipramine
OBJECTIVE: To report on the possible development of serotonin syndrome in a patient receiving clomipramine after clozapine was withdrawn from the treatment regimen.|serotonin syndrome|clomipramine
OBJECTIVE: To report on the possible development of serotonin syndrome in a patient receiving clomipramine after clozapine was withdrawn from the treatment regimen.|serotonin syndrome|clozapine
Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine.|serotonin syndrome|clomipramine
Possible serotonin syndrome associated with clomipramine after withdrawal of clozapine.|serotonin syndrome|clozapine
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|agitated|clomipramine
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|agitated|clozapine
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|behaving oddly|clomipramine
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|behaving oddly|clozapine
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|confused|clomipramine
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|confused|clozapine
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|shivering|clomipramine
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|shivering|clozapine
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|sweating profusely|clomipramine
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|sweating profusely|clozapine
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|tremulous|clomipramine
The day after clozapine was stopped, while he was still receiving clomipramine 150 mg/d, he began behaving oddly, started sweating profusely, shivering, and became tremulous, agitated, and confused.|tremulous|clozapine
Quinine induced coagulopathy--a near fatal experience.|coagulopathy|Quinine
The cause of his bleeding was a severe thrombocytopoaenia, induced by chronic ingestion of quinine.|severe thrombocytopoaenia|quinine
Dose-dependent olanzapine-associated leukopenia: three case reports.|leukopenia|olanzapine
These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.|agranulocytosis|olanzapine
These cases suggest the possibility that, in some patients, leukopenia or agranulocytosis during olanzapine treatment might be dose-related.|leukopenia|olanzapine
We report three cases of patients who developed leukopenia during olanzapine treatment.|leukopenia|olanzapine
CONCLUSION: This case illustrates a potential link between dermatologic and ocular 5-FU toxicities.|dermatologic and ocular 5-FU toxicities|5-FU
Differential diagnoses included ocular rosacea with cicatrizing conjunctivitis and 5-FU-induced ectropion.|ectropion|5-FU
DISCUSSION: Patients with 5-FU-induced ectropion experience tender, red, scaled lids, making contact lens wear difficult.|ectropion|5-FU
DISCUSSION: Patients with 5-FU-induced ectropion experience tender, red, scaled lids, making contact lens wear difficult.|tender, red, scaled lids|5-FU
Ectropion secondary to bolus injection of 5-fluorouracil.|Ectropion|5-fluorouracil
Exacerbation of 5-FU dermatologic toxicities in patients with preexisting conditions suggests the importance of aggressive ocular prophylaxis, using frequent ocular lubrication and topical steroid preparations with concurrent medical management of pre-existing dermatologic conditions.|dermatologic toxicities|5-FU
Presented is a case of acute renal failure induced by acetazolamide therapy for glaucoma.|acute renal failure|acetazolamide
Renal failure associated with acetazolamide therapy for glaucoma.|Renal failure|acetazolamide
This sulfonamide like nephropathy should be differentiated from acetazolamide-related calcium phosphate nephrolithiasis.|calcium phosphate nephrolithiasis|acetazolamide
Ischaemic colitis in a patient taking meloxicam.|Ischaemic colitis|meloxicam
Symptoms and endoscopic lesions quickly regressed within 1 week of meloxicam withdrawal.|endoscopic lesions|meloxicam
We describe a patient who presented with bloody diarrhoea after 15 mg meloxicam daily for 10 days for osteoarthritis.|bloody diarrhoea|meloxicam
We suggest that meloxicam might have intestinal toxic effects when taken in high doses, because of reduced COX-2 selectivity.|intestinal toxic effects|meloxicam
As these cases revealed, close monitoring of blood chemistry is mandatory after starting spironolactone, and patients should be advised to stop spironolactone immediately if diarrhoea develops.|diarrhoea|spironolactone
In patients with chronic heart failure, spironolactone added to conventional treatment may lead to serious and, occasionally, fatal hyperkalaemia.|serious and, occasionally, fatal hyperkalaemia|spironolactone
In some cases this seems to happen because spironolactone causes diarrhoea.|diarrhoea|spironolactone
Serious adverse events experienced by patients with chronic heart failure taking spironolactone.|Serious adverse events|spironolactone
We report a patient with advanced colonic carcinoma who was treated with concomitant chemoirradiation with oxaliplatin and developed a peculiar dermnatitis in the irradiated field after being exposed to subsequent chemotherapy with oxaliplatin.|dermnatitis|oxaliplatin
An 11-year-old boy developed a severe enteropathy 2 years after initiation of clofazimine treatment for graft-versus-host disease.|severe enteropathy|clofazimine
Clofazimine enteropathy caused by crystal deposition can be life-threatening.|enteropathy|Clofazimine
Clofazimine enteropathy caused by crystal deposition can be life-threatening.|life-threatening|Clofazimine
Clofazimine enteropathy in a pediatric bone marrow transplant recipient.|enteropathy|Clofazimine
She developed a severe urticarial rash 3 weeks following initiation of therapy with Enoxaparin.|severe urticarial rash|Enoxaparin
We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.|blurred vision|cibenzoline
We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.|cardiac failure|cibenzoline
We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.|cibenzoline intoxication|cibenzoline
We cared for a patient with progressive renal impairment who presented with blurred vision, QRS broadening and cardiac failure due to chronic cibenzoline intoxication.|QRS broadening|cibenzoline
Indolent aspergillus arthritis complicating fludarabine-based non-myeloablative stem cell transplantation.|aspergillus arthritis|fludarabine
We describe two patients with aspergillus arthritis of the knee joint following fludarabine-based non-myeloablative stem cell transplantation.|aspergillus arthritis of the knee joint|fludarabine
CONCLUSION: The present findings suggest that fluvoxamine can cause increased libido in some patients.|increased libido|fluvoxamine
Increased libido in a woman treated with fluvoxamine: a case report.|Increased libido|fluvoxamine
OBJECTIVE: The aim of this paper is to describe a case of increased libido during fluvoxamine therapy.|increased libido|fluvoxamine
RESULTS: The patient, a 27-year-old married Japanese woman with borderline personality disorder, developed an increased libido with the administration of fluvoxamine.|increased libido|fluvoxamine
The increased libido disappeared after fluvoxamine was discontinued.|increased libido|fluvoxamine
An infant who developed pancreatitis during meglumine antimoniate treatment for visceral leishmaniasis and who was successfully treated with a combination of allopurinol and ketoconazole is reported.|pancreatitis|meglumine antimoniate
Successful treatment of visceral leishmaniasis with allopurinol plus ketoconazole in an infant who developed pancreatitis caused by meglumine antimoniate.|pancreatitis|meglumine antimoniate
CONCLUSIONS: This case report showed that the clinical appearance of Hashimoto's disease after IFN-alpha therapy for chronic C hepatitis in our patient was associated with a specific genetic predisposition (DR5) for this pathology.|Hashimoto's disease|IFN-alpha
Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of thyroid disorders during the IFN-alpha treatment.|autoimmune thyroiditis|IFN-alpha
Further studies are necessary to evaluate whether the study of HLA antigens may be a very useful tool to detect the patients with a predisposition to develop autoimmune thyroiditis, in order to make a early diagnosis of thyroid disorders during the IFN-alpha treatment.|thyroid disorders|IFN-alpha
Hashimoto's disease during interferon-alpha therapy in a patient with pre-treatment negative anti-thyroid autoantibodies and with the specific genetic susceptibility to the thyroid disease.|Hashimoto's disease|interferon-alpha
OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.|Hashimoto's disease|IFN-alpha
OBJECTIVES: The authors described a case of Hashimoto's disease during interferon-alpha (IFN-alpha) treatment for chronic viral C hepatitis in a patient with the specific genetic susceptibility associated with the thyroid disease.|Hashimoto's disease|interferon-alpha
During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.|peripheral edema|omeprazole
During dose-finding studies for intravenous proton pump inhibitors omeprazole and pantoprazole, three of six young female volunteers receiving omeprazole and two young female volunteers receiving pantoprazole developed peripheral edema within 8 hr when high doses of the proton pump inhibitors were applied by continuous infusion together with large volumes of fluid.|peripheral edema|pantoprazole
Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.|Pheripheral edema|lansoprazole
Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.|Pheripheral edema|omeprazole
Pheripheral edema was observed in five female patients after taking proton pump inhibitors omeprazole, lansoprazole, or pantoprazole for 7-15 days for peptic acid diseases in recommended standard doses.|Pheripheral edema|pantoprazole
Motor fluctuations appear after 2-3 years of levodopa treatment, and affect at least 50% of patients after five years.|Motor fluctuations|levodopa
CONCLUSION: Significant weight loss is a potential adverse event in patients with rheumatoid arthritis treated with leflunomide.|weight loss|leflunomide
Leflunomide-associated weight loss in rheumatoid arthritis.|weight loss|Leflunomide
METHODS: We queried 35 rheumatologists at the Robert Breck Brigham Arthritis Center to determine if weight loss had occurred as an adverse event in patients treated with leflunomide between November 1998 and January 2000.|weight loss|leflunomide
OBJECTIVE: To determine the frequency of weight loss in patients treated with leflunomide for rheumatoid arthritis at an arthritis referral center.|weight loss|leflunomide
RESULTS: Five of 70 patients who had begun leflunomide therapy had significant weight loss that could not be linked to other identifiable etiologies.|weight loss|leflunomide
It is increasingly recognized that dose adjustment of oral valacyclovir in renal failure is necessary to avoid neurotoxicity.|neurotoxicity|valacyclovir
Neurotoxicity of valacyclovir in peritoneal dialysis: a pharmacokinetic study.|Neurotoxicity|valacyclovir
She developed neurotoxicity with an adjustment dosage of valacyclovir for a cutaneous zoster infection.|neurotoxicity|valacyclovir
Avascular necrosis of the femoral head in patients with prostate cancer treated with cyproterone acetate and radiotherapy.|Avascular necrosis of the femoral head|cyproterone acetate
We report the case histories of two patients with histologically confirmed adenocarcinoma of the prostate, both of whom had been treated with steroidal anti-androgen therapy in the form of cyproterone acetate prior to radical or palliative pelvic irradiation, and who subsequently developed femoral head avascular necrosis.|femoral head avascular necrosis|cyproterone acetate
Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval.|polymorphic ventricular tachycardia|Levofloxacin
We report the first case of polymorphic ventricular tachycardia with normal QT interval associated with the oral use of levofloxacin in the absence of other etiologies known to cause these arrhythmias.|polymorphic ventricular tachycardia|levofloxacin
So far, few cases of pulmonary side effects caused by ticlopidine have been reported.|pulmonary side effects|ticlopidine
Special care should be taken when pulmonary symptoms appear in association with ticlopidine treatment.|pulmonary symptoms|ticlopidine
Ticlopidine-induced interstitial pulmonary disease: a case report.|interstitial pulmonary disease|Ticlopidine
We report a case of interstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with ticlopidine.|interstitial pulmonary disease|ticlopidine
We report a case of interstitial pulmonary disease that occurred together with lymphocytic colitis during treatment with ticlopidine.|lymphocytic colitis|ticlopidine
A patient that received methadone for cancer-associated pain developed myoclonus as a side effect.|myoclonus|methadone
Methadone-induced myoclonus in advanced cancer.|myoclonus|Methadone
OBJECTIVE: To report a case of fatal hyperkalemia owing to succinylcholine administration in a patient with mucositis secondary to chemotherapy.|fatal hyperkalemia|succinylcholine
Succinylcholine-induced hyperkalemia in a patient with mucositis secondary to chemotherapy.|hyperkalemia|Succinylcholine
We believe that mucositis was a contributing factor to this case of fatal hyperkalemia after administration of succinylcholine, with a mechanism similar to that reported with thermal injury.|fatal hyperkalemia|succinylcholine
Cutaneous seeding after ultrasound-guided percutaneous ethanol injection for treatment of hepatocellular carcinoma.|Cutaneous seeding|ethanol injection
We describe a case of needle-track cutaneous seeding of hepatocellular carcinoma (HCC) after sonographically guided percutaneous ethanol injection (PEI).|cutaneous seeding|ethanol injection
Adenosine-induced ventricular fibrillation.|ventricular fibrillation|Adenosine
However, adenosine shortens the antegrade refractoriness of accessory atrioventricular connections and may cause acceleration of the ventricular rate during atrial fibrillation.|acceleration of the ventricular rate|adenosine
We observed ventricular fibrillation in 2 patients who presented to the emergency department with pre-excited atrial fibrillation and were given 12 mg of adenosine.|ventricular fibrillation|adenosine
After the dose of methylprednisolone was reduced from 40 mg to 20 mg i.v. q6h and shifted to other anti-asthma treatment by procaterol metered dose inhaler via spacer, the psychotic reaction disappeared a few hours later.|psychotic reaction|methylprednisolone
Continuous EEG monitoring is helpful in managing seizures that occur as a complication of CBZ OD, after the course of recovery or worsening, and in providing assistance with prognosis.|seizures|CBZ
Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.|cortical hyperexcitability|CBZ
Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.|cranial nerve areflexia|CBZ
Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.|profound burst-suppression EEG pattern|CBZ
Massive CBZ OD may produce a reversible encephalopathy that includes cortical hyperexcitability, a profound burst-suppression EEG pattern, and cranial nerve areflexia.|reversible encephalopathy|CBZ
Massive plasmocytosis due to methimazole-induced bone marrow toxicity.|bone marrow toxicity|methimazole
Massive plasmocytosis due to methimazole-induced bone marrow toxicity.|Massive plasmocytosis|methimazole
To our knowledge this is the first report of pancytopenia due to MMI, where the usual hypoplasia found is replaced by massive plasmocytosis.|massive plasmocytosis|MMI
To our knowledge this is the first report of pancytopenia due to MMI, where the usual hypoplasia found is replaced by massive plasmocytosis.|pancytopenia|MMI
We report a case of fulminant hepatic failure associated with didanosine and masquerading as a surgical abdomen and compare the clinical, biologic, histologic, and ultrastructural findings with reports described previously.|fulminant hepatic failure|didanosine
This report details a case of bilateral avascular necrosis of the femoral heads in a patient receiving 'standard' doses of dexamethasone as part of the antiemetic regimen used in cisplatin-based combination chemotherapy.|bilateral avascular necrosis of the femoral heads|dexamethasone
Although no coagulation study was done and the Meckel's diverticulum is normally associated with bleeding, the particular intensity of the following hemorrhage may have been favored by metformin.|hemorrhage|metformin
An obese patient, not diabetic, treated with metformin for some weeks, was referred to us with severe inferior digestive hemorrhage, diagnosed with Meckel's diverticulum.|severe inferior digestive hemorrhage|metformin
Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection?|Digestive hemorrhage|metformin
Ulcer became worse after tobramycin and gentamycin treatment for 2 days.|Ulcer became worse|gentamycin
Ulcer became worse after tobramycin and gentamycin treatment for 2 days.|Ulcer became worse|tobramycin
Possible linkage of amprenavir with intracranial bleeding in an HIV-infected hemophiliac.|intracranial bleeding|amprenavir
The bleeding resolved on discontinuation of APV.|bleeding|APV
We report the occurrence of spontaneous intracranial bleeding in an human immunodeficiency virus (HIV)-infected adolescent with hemophilia A who was receiving amprenavir (APV).|intracranial bleeding|amprenavir
According to the Naranjo probability scale, the relationship of gemcitabine treatment with cutaneous eruption in our patient is possible.|cutaneous eruption|gemcitabine
CONCLUSIONS: We report the first case of gemcitabine-induced LABD.|LABD|gemcitabine
Linear immunoglobulin A bullous dermatosis induced by gemcitabine.|Linear immunoglobulin A bullous dermatosis|gemcitabine
OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.|LABD|gemcitabine
OBJECTIVE: To report a case of linear immunoglobulin (Ig) A bullous dermatosis (LABD) induced by gemcitabine.|linear immunoglobulin (Ig) A bullous dermatosis|gemcitabine
Twenty-four hours after the administration of gemcitabine, a symmetric, bullous, herpetiform eruption appeared on his trunk and upper limbs.|symmetric, bullous, herpetiform eruption|gemcitabine
Vancomycin is the most frequently implicated drug, but other agents have been reported to cause LABD.|LABD|Vancomycin
Although taxol has shown significant activity in advanced ovarian cancer, peripheral neuropathy is likely to become the major dose-limiting toxicity.|peripheral neuropathy|taxol
A rare case of advanced ovarian carcinoma who developed difficulty walking 25 days after treatment with weekly paclitaxel.|difficulty walking|paclitaxel
We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol (80 mg/m(2)x3).|difficulty walking|taxol
We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol (80 mg/m(2)x3).|loss of proprioception|taxol
We describe a case of advanced ovarian carcinoma who developed difficulty walking because of marked pain in the lower extremities and loss of proprioception 25 days after treatment with weekly taxol (80 mg/m(2)x3).|marked pain|taxol
Relief by naloxone of morphine-induced spasm of the sphincter of Oddi in a post-cholecystectomy patient.|spasm|morphine
We present the case of a patient who had undergone cholecystectomy previously, but in whom morphine given in the Emergency Department precipitated pain consistent with biliary colic; the pain resolved promptly after administration of naloxone.|biliary colic|morphine
We present the case of a patient who had undergone cholecystectomy previously, but in whom morphine given in the Emergency Department precipitated pain consistent with biliary colic; the pain resolved promptly after administration of naloxone.|pain|morphine
Myasthenia gravis during low-dose IFN-alpha therapy for chronic hepatitis C.|Myasthenia gravis|IFN-alpha
A patient with rheumatoid arthritis developed an acute intrahepatic cholestasis after 100 mg of sodium aurothiomalate.|intrahepatic cholestasis|sodium aurothiomalate
Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.|Acute lung injury|5-fluorouracil
Acute lung injury associated with 5-fluorouracil and oxaliplatinum combined chemotherapy.|Acute lung injury|oxaliplatinum
Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.|bilateral patchy pulmonary infiltrates|5-fluorouracil
Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.|bilateral patchy pulmonary infiltrates|oxaliplatinum
Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.|Diarrhoea|5-fluorouracil
Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.|Diarrhoea|oxaliplatinum
Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.|T-CD4+ lymphopenia|5-fluorouracil
Diarrhoea, T-CD4+ lymphopenia and bilateral patchy pulmonary infiltrates developed in a male 60 yrs of age, who was treated with oxaliplatinum and 5-fluorouracil for unresectable rectum carcinoma.|T-CD4+ lymphopenia|oxaliplatinum
It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.|pulmonary adverse reaction|5-fluorouracil
It is concluded that the aforementioned pathological manifestations were due to chemotherapy and included a pulmonary adverse reaction, a feature never previously associated with oxaliplatinum and 5-fluorouracil regimens.|pulmonary adverse reaction|oxaliplatinum
BACKGROUND: Accutane a teratogenic prescription drug licensed to treat severe, recalcitrant nodular acne.|teratogenic|Accutane
RESULTS: The estimated number of Accutane prescriptions for reproductive-aged women has more than doubled in the past 10 years; it is the most widely used teratogenic drug in the United States, with approximately 2.5 per 1,000 reproductive-aged women exposed to Accutane in 1999.|teratogenic|Accutane
A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.|high fever|pranlukast
A 62-year-old woman treated with pranlukast for 2 months developed interstitial pneumonitis with a high fever.|interstitial pneumonitis|pranlukast
Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.|interstitial pneumonia|ONO-1078
Acute interstitial pneumonia induced by ONO-1078 (pranlukast), a leukotriene receptor antagonist.|interstitial pneumonia|pranlukast
An asymptomatic HIV-infected woman experienced right-sided renal colicky pain during treatment with indinavir.|renal colicky pain|indinavir
Indinavir-associated nephrolithiasis and chronic interstitial nephritis were the only possible causes identified in this patient.|interstitial nephritis|Indinavir
Indinavir-associated nephrolithiasis and chronic interstitial nephritis were the only possible causes identified in this patient.|nephrolithiasis|Indinavir
Papillary necrosis associated with the HIV protease inhibitor indinavir.|Papillary necrosis|indinavir
Physicians should be aware that indinavir nephrolithiasis may cause papillary necrosis.|nephrolithiasis|indinavir
Physicians should be aware that indinavir nephrolithiasis may cause papillary necrosis.|papillary necrosis|indinavir
The HIV protease inhibitor indinavir may cause nephrolithiasis and interstitial nephritis.|interstitial nephritis|indinavir
The HIV protease inhibitor indinavir may cause nephrolithiasis and interstitial nephritis.|nephrolithiasis|indinavir
The renal consequences of indinavir-associated nephrotoxicity are uncertain.|nephrotoxicity|indinavir
We report a case of papillary necrosis in a patient treated with indinavir.|papillary necrosis|indinavir
We describe 2 male patients, a 49-year-old with psoriatic arthritis and impaired renal function and a 43-year-old renal transplant recipient, who both sustained a marked decline in glomerular filtration rate in conjunction with a selective inhibitor of cyclooxygenase-2 (COX-2), rofecoxib.|decline in glomerular filtration rate|rofecoxib
CONCLUSIONS: LTG overdose may result in a severe but reversible encephalopathy, a previously undescribed phenomenon.|encephalopathy|LTG
Evaluation revealed elevated serum LTG levels and no other etiology for encephalopathy.|elevated serum LTG levels|LTG
METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.|stuporous|lamotrigine
METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.|stuporous|LTG
METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.|stuporous|valproic acid
METHODS: A 55-year-old woman became stuporous after overdose with lamotrigine (LTG) and valproic acid (VPA) tablets.|stuporous|VPA
PURPOSE: To report that acute lamotrigine poisoning may result in severe encephalopathy.|encephalopathy|lamotrigine
Stupor from lamotrigine toxicity.|Stupor|lamotrigine
The cause of death was determined to be acute intoxication by olanzapine, and the manner of death was accidental.|acute intoxication|olanzapine
This article describes the case of a 25-year-old man found dead at home who had been prescribed olanzapine for schizophrenia.|dead|olanzapine
Lichenoid drug eruption to salsalate.|Lichenoid drug eruption|salsalate
This eruption emerged after 1 month of therapy with salsalate, persisted for as long as salsalate was administered, and cleared within 3 weeks of discontinuing the medication.|eruption|salsalate
We describe a patient who experienced a lichenoid eruption after the initiation of salsalate for relief of arthritic pain.|lichenoid eruption|salsalate
Amphotericin B-induced seizures in a patient with AIDS.|seizures|Amphotericin B
CASE SUMMARY: A 46-year-old African-American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B, then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time.|grand mal seizures|amphotericin B
CONCLUSIONS: Amphotericin B seems to be the probable cause of the seizures.|seizures|Amphotericin B
Despite administration of phenytoin and lorazepam, the seizures persisted and occurred only during amphotercin B administration.|seizures|amphotercin B
Didanosine also has a potential for inducing seizures.|seizures|Didanosine
OBJECTIVE: To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion.|seizure|amphotericin B
The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient.|seizures|amphotericin B
To date, only three cases of seizures associated with amphotericin B have been reported in the literature, but healthcare providers should be aware of the potential for this rare adverse effect.|seizures|amphotericin B
Vocal cord paralysis as a consequence of peritonsillar infiltration with bupivacaine.|Vocal cord paralysis|bupivacaine
We present the case of a 5-year-old girl who developed bilateral vocal cord paralysis following preoperative peritonsillar bupivacaine infiltration.|bilateral vocal cord paralysis|bupivacaine
A 53 year old Greenlandic male was admitted twice over a period of 4 years with a new complete right bundle branch block after ingestion of 10 g and 4 g of carbamazepine respectively.|right bundle branch block|carbamazepine
Carbamazepine induced right bundle branch block in a Greenlandic patient.|right bundle branch block|Carbamazepine
Cicatricial entropion associated with chronic dipivefrin application.|Cicatricial entropion|dipivefrin
CONCLUSIONS: Cicatrization in the substantia propria of the conjunctiva by excessive lymphocytic infiltration after topically administered antiglaucoma drugs including dipivefrin is a possible mechanism of action for entropion.|entropion|dipivefrin
Nine eyes from 6 patients, 74 years to 90 years of age, referred by ophthalmologists for repair of cicatricial entropion after at least 2 years of twice-a-day application of dipivefrin.|cicatricial entropion|dipivefrin
PURPOSE: To report patients who presented to the oculoplastics department for repair of cicatrical entropion after topical use of dipivefrin.|cicatrical entropion|dipivefrin
A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.|constellation of dermatitis|sulphasalazine
A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.|fever|sulphasalazine
A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.|hepatitis|sulphasalazine
A 34-year-old lady developed a constellation of dermatitis, fever, lymphadenopathy and hepatitis, beginning on the 17th day of a course of oral sulphasalazine for sero-negative rheumatoid arthritis.|lymphadenopathy|sulphasalazine
It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week sulphasalazine syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine.|fatal|sulphasalazine
It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week sulphasalazine syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine.|fatal|sulphasalazine
It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week sulphasalazine syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine.|immunoallergic reaction|sulphasalazine
It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week sulphasalazine syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine.|immunoallergic reaction|sulphasalazine
It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week sulphasalazine syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine.|sulphasalazine syndrome|sulphasalazine
It is thought that the clinico-pathological features and chronology of this case bore the hallmarks of the so-called "3-week sulphasalazine syndrome", a rare, but often fatal, immunoallergic reaction to sulphasalazine.|sulphasalazine syndrome|sulphasalazine
The 3-week sulphasalazine syndrome strikes again.|sulphasalazine syndrome|sulphasalazine
Interestingly, the use of carboplatin (CBDCA) and VDS in the subsequent treatment course was well tolerated indicating that the SIADH was most likely to have been induced by administration of CDDP.|SIADH|CDDP
Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.|SIADH|cisplatin
Syndrome of inappropriate secretion of ADH (SIADH) following cisplatin administration in a pulmonary adenocarcinoma patient with a malignant pleural effusion.|Syndrome of inappropriate secretion of ADH|cisplatin
We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|SIADH|CDDP
We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|SIADH|cisplatin
We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|SIADH|VDS
We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|SIADH|vindesine
We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|syndrome of inappropriate secretion of antidiuretic hormone|CDDP
We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|syndrome of inappropriate secretion of antidiuretic hormone|cisplatin
We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|syndrome of inappropriate secretion of antidiuretic hormone|VDS
We report a patient with pulmonary adenocarcinoma complicated by the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following systemic chemotherapy with cisplatin (CDDP) and vindesine (VDS).|syndrome of inappropriate secretion of antidiuretic hormone|vindesine
After extensive neurological 'work up', we realized that the anisocoria was related to the transdermal scopolamine patch that we had prescribed for weaning off the opioid.|anisocoria|scopolamine
Anisocoria from transdermal scopolamine.|Anisocoria|scopolamine
De novo absence status of late onset following withdrawal of lorazepam: a case report.|De novo absence status|lorazepam
The aim of this report is to describe the clinical and electroencephalographic findings seen in an elderly woman without previous history of seizures who developed a nonconvulsive generalized status epilepticus following acute withdrawal of lorazepam.|nonconvulsive generalized status epilepticus|lorazepam
Early recognition of hereditary motor and sensory neuropathy type 1 can avoid life-threatening vincristine neurotoxicity.|life-threatening vincristine neurotoxicity|vincristine
Recognizing early signs of HMSN, such as areflexia and pes cavus deformity, can prevent severe neurotoxicity of polychemotherapy by avoiding vincristine.|severe neurotoxicity|vincristine
The disease predisposes to severe vincristine neurotoxicity.|vincristine neurotoxicity|vincristine
We report a 31-year-old women with recurrent Hodgkin's lymphoma and unrecognized HMSN-1 who developed severe motor neuropathy 3 weeks after the first cycle of treatment including 2 mg of vincristine.|severe motor neuropathy|vincristine
Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate.|asymptomatic hepatitis|amodiaquine
Acute asymptomatic hepatitis in a healthy normal volunteer exposed to 2 oral doses of amodiaquine and artesunate.|asymptomatic hepatitis|artesunate
This report describes an unexpected drug-induced hepatitis in a previously healthy young woman exposed to 2 doses of amodiaquine and artesunate.|hepatitis|amodiaquine
This report describes an unexpected drug-induced hepatitis in a previously healthy young woman exposed to 2 doses of amodiaquine and artesunate.|hepatitis|artesunate
Systemic allergic contact dermatitis to 8-methoxypsoralen (8-MOP).|Systemic allergic contact dermatitis|8-methoxypsoralen
Systemic allergic contact dermatitis to 8-methoxypsoralen (8-MOP).|Systemic allergic contact dermatitis|8-MOP
We describe a patient who had a systemic allergic contact dermatitis to 8-MOP develop during her second course of PUVA treatment for psoriasis.|systemic allergic contact dermatitis|8-MOP
A 33-year-old man with a history of recreational benztropine abuse presented to the emergency department with confusion, abdominal pain, and distention.|abdominal pain|benztropine
A 33-year-old man with a history of recreational benztropine abuse presented to the emergency department with confusion, abdominal pain, and distention.|confusion|benztropine
A 33-year-old man with a history of recreational benztropine abuse presented to the emergency department with confusion, abdominal pain, and distention.|distention|benztropine
Agranulocytosis and granulocytopenia associated with quetiapine.|Agranulocytosis|quetiapine
Agranulocytosis and granulocytopenia associated with quetiapine.|granulocytopenia|quetiapine
CONCLUSION: Although a definite association has not been proven, clinicians should be aware of the possibility of agranulocytosis while using quetiapine.|agranulocytosis|quetiapine
METHOD: We describe three case-reports concerning haematological adverse effects of quetiapine.|haematological adverse effects|quetiapine
RESULTS: Quetiapine was associated with leucopenia in two patients and clinically apparent agranulocytosis in one patient.|agranulocytosis|Quetiapine
RESULTS: Quetiapine was associated with leucopenia in two patients and clinically apparent agranulocytosis in one patient.|leucopenia|Quetiapine
CONCLUSIONS: There is very little published information regarding ofloxacin-induced toxic epidermal necrolysis.|toxic epidermal necrolysis|ofloxacin
However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.|Stevens-Johnson syndrome|ofloxacin
However, a large case-control study included three cases of either Stevens-Johnson syndrome or toxic epidermal necrolysis associated with ofloxacin use, but no details of the cases were given.|toxic epidermal necrolysis|ofloxacin
It is hoped that this case report creates awareness that ofloxacin-induced toxic epidermal necrolysis is possible.|toxic epidermal necrolysis|ofloxacin
OBJECTIVE: To report a fatal case of toxic epidermal necrolysis in a man who was treated with oral ofloxacin for epididymitis.|toxic epidermal necrolysis|ofloxacin
Ofloxacin: a probable cause of toxic epidermal necrolysis.|toxic epidermal necrolysis|Ofloxacin
This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.|toxic epidermal necrolysis|ofloxacin
This report rules out other causes of toxic epidermal necrolysis and implicates ofloxacin in what appears to be an atypical presentation of drug-induced toxic epidermal necrolysis.|toxic epidermal necrolysis|ofloxacin
A boy with chronic neutropenia and recurrent inflammatory skin lesions developed multiple erythematous nodules following administration of G-CSF.|multiple erythematous nodules|G-CSF
A girl with cystic fibrosis and cyclic neutropenia developed an erythematous papular eruption without fever or neutrophilia 7 months after commencing therapy with G-CSF.|erythematous papular eruption|G-CSF
Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy.|Neutrophilic dermatoses|G-CSF
Neutrophilic dermatoses in two children with idiopathic neutropenia: association with granulocyte colony-stimulating factor (G-CSF) therapy.|Neutrophilic dermatoses|granulocyte colony-stimulating factor
Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor (G-CSF) for treatment of idiopathic neutropenia.|neutrophilic skin lesions|G-CSF
Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor (G-CSF) for treatment of idiopathic neutropenia.|neutrophilic skin lesions|granulocyte colony-stimulating factor
Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor (G-CSF) for treatment of idiopathic neutropenia.|Painful|G-CSF
Painful neutrophilic skin lesions were observed in two children receiving granulocyte colony-stimulating factor (G-CSF) for treatment of idiopathic neutropenia.|Painful|granulocyte colony-stimulating factor
We believe that these skin eruptions belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by G-CSF therapy.|neutrophilic dermatoses|G-CSF
We believe that these skin eruptions belong to a spectrum of neutrophilic dermatoses that can be induced or aggravated by G-CSF therapy.|skin eruptions|G-CSF
There is a putative role of liothyronine administration in precipitating or activating hyperthyroidism.|hyperthyroidism|liothyronine
Triiodothyronine-induced thyrotoxicosis in ophthalmic Graves disease.|thyrotoxicosis|Triiodothyronine
This case report describes the development of asymptomatic visual field defects (VFDs) in a psychiatric patient with bipolar disorder receiving adjunctive tiagabine treatment.|VFDs|tiagabine
This case report describes the development of asymptomatic visual field defects (VFDs) in a psychiatric patient with bipolar disorder receiving adjunctive tiagabine treatment.|visual field defects|tiagabine
Pulmonary toxicity with mefloquine.|Pulmonary toxicity|mefloquine
This is the second report of acute lung injury and diffuse alveolar damage caused by mefloquine.|acute lung injury|mefloquine
This is the second report of acute lung injury and diffuse alveolar damage caused by mefloquine.|diffuse alveolar damage|mefloquine
This report presents a case of acute lung injury developing within hours after administration of mefloquine for a low-level Plasmodium falciparum malaria, which was persistent despite halofantrine therapy.|acute lung injury|mefloquine
An adult male presented with central blindness after ingesting methanol.|central blindness|methanol
Reversal of severe methanol-induced visual impairment: no evidence of retinal toxicity due to fomepizole.|visual impairment|methanol
Extra caution should be taken in using octreotide or its long-acting analog in patients otherwise predisposed to intrahepatic bile stasis.|intrahepatic bile stasis|octreotide
Gallstones and bile sludge are common side effects of octreotide therapy but rarely become symptomatic or require treatment.|bile sludge|octreotide
Gallstones and bile sludge are common side effects of octreotide therapy but rarely become symptomatic or require treatment.|Gallstones|octreotide
Hepatolithiasis (intrahepatic stone) during octreotide therapy for acromegaly: a case report.|Hepatolithiasis|octreotide
In addition to its known effect on gallbladder stasis, octreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation.|alters bile acid composition|octreotide
In addition to its known effect on gallbladder stasis, octreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation.|gallbladder stasis|octreotide
In addition to its known effect on gallbladder stasis, octreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation.|hasten intrahepatic sludge|octreotide
In addition to its known effect on gallbladder stasis, octreotide alters bile acid composition and may thus hasten intrahepatic sludge and stone formation.|stone formation|octreotide
This is the first reported case of hepatolithiasis during octreotide therapy.|hepatolithiasis|octreotide
We report a case of hepatolithiasis (intrahepatic stone) complicated by gram-negative sepsis in a 37 year old male with acromegaly being treated with octreotide.|hepatolithiasis|octreotide
However, in the mid-to-late 1980s, a series of letters to the editor and case reports announced an association between tamoxifen therapy in women with breast cancer and the development of endometrial carcinoma.|endometrial carcinoma|tamoxifen
In this healthy population, the relative risk of developing endometrial carcinoma in the tamoxifen arm was 2.54, although when stratified by age, in women over 50, the risk grew to 4.01.|endometrial carcinoma|tamoxifen
INH, which is a leading cause of drug eruptions in the above group of drugs was withdrawn.|drug eruptions|INH
Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.|anagen effluvium|Isonicotinic acid hydrazide
Isonicotinic acid hydrazide induced anagen effluvium and associated lichenoid eruption.|lichenoid eruption|Isonicotinic acid hydrazide
Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.|anagen effluvium|INH
Such anagen effluvium with lichenoid eruption following INH therapy has not been observed previously.|lichenoid eruption|INH
Linear IgA bullous dermatosis occurring after carbamazepine.|Linear IgA bullous dermatosis|carbamazepine
We report a patient who experienced LABD shortly after starting carbamazepine therapy.|LABD|carbamazepine
After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|agitation|metoclopramide
After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|confusion|metoclopramide
After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|diaphoresis|metoclopramide
After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|fever|metoclopramide
After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|hypertension|metoclopramide
After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|tachycardia|metoclopramide
After a second dose of metoclopramide, these symptoms recurred and were associated with confusion, agitation, fever, diaphoresis, tachypnea, tachycardia, and hypertension.|tachypnea|metoclopramide
CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.|extrapyramidal reactions|metoclopramide
CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.|extrapyramidal reactions|sertraline
CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.|extrapyramidal reactions|venlafaxine
CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.|serotonin syndrome|metoclopramide
CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.|serotonin syndrome|sertraline
CONCLUSIONS: Clinicians should be aware of a risk of serotonin syndrome with serious extrapyramidal reactions in patients receiving sertraline or venlafaxine when metoclopramide is coadministered even in a single, conventional dose.|serotonin syndrome|venlafaxine
OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.|extrapyramidal movement disorders|metoclopramide
OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.|extrapyramidal movement disorders|sertraline
OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.|extrapyramidal movement disorders|venlafaxine
OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.|serotonin syndrome|metoclopramide
OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.|serotonin syndrome|sertraline
OBJECTIVE: To report 2 cases of serotonin syndrome with serious extrapyramidal movement disorders occurring when metoclopramide was coadministered with sertraline or venlafaxine.|serotonin syndrome|venlafaxine
Serotonin syndrome caused by selective serotonin reuptake-inhibitors-metoclopramide interaction.|Serotonin syndrome|metoclopramide
She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.|agitation|metoclopramide
She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.|diaphoresis|metoclopramide
She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.|dysarthria|metoclopramide
She was administered metoclopramide because of nausea and, within 2 hours, developed agitation, dysarthria, diaphoresis, and a movement disorder.|movement disorder|metoclopramide
She was admitted following a fall and, after being given metoclopramide, developed movement disorder and a period of unresponsiveness.|movement disorder|metoclopramide
She was admitted following a fall and, after being given metoclopramide, developed movement disorder and a period of unresponsiveness.|unresponsiveness|metoclopramide
A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol.|malignant neuroleptic syndrome|haloperidol
BACKGROUND: reports on delated cutaneous reactions to captopril have been seldom reported.|delated cutaneous reactions|captopril
Captopril is an angiotensin-converting enzyme (ACE) inhibitor and their cutaneous side-effects are documented, but little has been published concerning the usefulness of patch test when they occur.|cutaneous side-effects|Captopril
Dermatitis to captopril.|Dermatitis|captopril
We presented the case of a patient who developed a cutaneous reaction induced by captopril with positive patch test.|cutaneous reaction|captopril
A 62-year-old Caucasian man with atrial fibrillation who was taking warfarin reported an episode of hematochezia; his international normalized ratio (INR) was 1.74.|hematochezia|warfarin
Warfarin-associated bleeding complication saved life.|bleeding|Warfarin
Warfarin-associated bleeding generally is considered deleterious; however, in our patient it unmasked an early stage of colon cancer and thus may have saved the patient's life.|bleeding|Warfarin
A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B.|dilated cardiomyopathy|interferon alpha
A case of polymyositis with dilated cardiomyopathy associated with interferon alpha treatment for hepatitis B.|polymyositis|interferon alpha
In this case, interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.|cardiomyopathy|interferon alpha
In this case, interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B.|polymyositis|interferon alpha
Polymyositis is a rare complication of interferon alpha treatment as a result of immune-modulating role of the drug itself.|Polymyositis|interferon alpha
To treat hepatitis B, interferon alpha was administered until the proximal muscle weakness developed.|muscle weakness|interferon alpha
Long-term follow-up after neoplastic seeding complicating percutaneous ethanol injection for treatment of hepatocellular carcinoma.|neoplastic seeding|ethanol
We describe a case of subcutaneous metastasis along the needle track after percutaneous ethanol injection (PEI) for treatment of hepatocellular carcinoma.|subcutaneous metastasis|ethanol
Aggressive endometrial carcinoma in a breast cancer patient treated with tamoxifen with normal transvaginal ultrasonography.|Aggressive endometrial carcinoma|tamoxifen
Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recommended.|endometrial disorders|tamoxifen
Since tamoxifen therapy can induce endometrial disorders, surveillance schemes of women taking tamoxifen have been recommended.|endometrial disorders|tamoxifen
We described a very atypical case of a high stage, high grade endometrial cancer associated with tamoxifen in a 64-year-old woman with a past history of breast cancer.|endometrial cancer|tamoxifen
Beginning ductopenia was present in two, suggesting that itraconazole might be responsible for the occurrence of prolonged drug-induced cholangiopathy.|cholangiopathy|itraconazole
Beginning ductopenia was present in two, suggesting that itraconazole might be responsible for the occurrence of prolonged drug-induced cholangiopathy.|ductopenia|itraconazole
CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.|cholestatic pattern of injury|Itraconazole
CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.|damage to the interlobular bile ducts|Itraconazole
CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.|ductopenia|Itraconazole
CONCLUSIONS: Itraconazole-induced liver injury presents with a cholestatic pattern of injury with damage to the interlobular bile ducts, possibly leading to ductopenia.|liver injury|Itraconazole
Hepatotoxicity related to itraconazole: report of three cases.|Hepatotoxicity|itraconazole
METHODS: Three patients with apparent itraconazole-induced liver injury were studied.|liver injury|itraconazole
The occurrence of acute hepatitis is best known for ketoconazole.|hepatitis|ketoconazole
We report on three patients who developed acute liver damage during therapy with itraconazole, and in whom liver biopsy specimens were obtained.|liver damage|itraconazole
We suggest that itraconazole should be added to the list of drugs that may be responsible for a drug-induced vanishing bile duct syndrome.|vanishing bile duct syndrome|itraconazole
With itraconazole, hepatotoxic reactions have only very rarely been reported, and histologic data are lacking.|hepatotoxic|itraconazole
Thrombotic stroke associated with the use of porcine factor VIII in a patient with acquired haemophilia.|Thrombotic stroke|porcine factor VIII
We have recently encountered a patient with acquired haemophilia who developed a thrombotic left middle cerebral artery distribution stroke while being treated with pFVIII.|thrombotic left middle cerebral artery distribution stroke|pFVIII
We speculate that platelet activation induced by pFVIII may have contributed to thrombosis and suggest that pFVIII be used with caution in elderly patients with pre-existing cardiovascular risk factors.|thrombosis|pFVIII
Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.|Cutaneous sarcoidosis|interferon alfa
Cutaneous sarcoidosis during interferon alfa and ribavirin treatment of hepatitis C virus infection: two cases.|Cutaneous sarcoidosis|ribavirin
There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.|granulomatosis|interferon alfa
There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.|granulomatosis|interferon alfa
There have been more than 20 observations of the appearance or aggravation of this granulomatosis with interferon alfa and more recently with the combination of interferon alfa plus ribavirin.|granulomatosis|ribavirin
We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.|sarcoidosis|interferon alfa
We report two new cases of sarcoidosis in two patients with hepatitis C virus infection treated with interferon alfa and ribavirin.|sarcoidosis|ribavirin
CONCLUSIONS: Although mirtazapine offers clinicians a combination of strong efficacy and good safety, we suggest bearing SS in mind when prescribing this drug, especially in frail, elderly patients with underlying chronic conditions.|SS|mirtazapine
DISCUSSION: A review of the cases of SS with implication of mirtazapine as the cause was performed.|SS|mirtazapine
OBJECTIVE: To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction.|serotonin syndrome|mirtazapine
OBJECTIVE: To document a case of serotonin syndrome (SS) associated with mirtazapine monotherapy, review the previously reported cases of SS associated with this tetracyclic antidepressant, and discuss the possible pathogenic mechanisms leading to this serious adverse drug reaction.|SS|mirtazapine
Severe serotonin syndrome induced by mirtazapine monotherapy.|serotonin syndrome|mirtazapine
Pulmonary toxicity secondary to procarbazine.|Pulmonary toxicity|procarbazine
A 64-year-old man presented with proteinuria during postoperative interferon (IFN)-beta therapy against malignant melanoma.|proteinuria|interferon (IFN)-beta
Minimal change nephrotic syndrome developing during postoperative interferon-beta therapy for malignant melanoma.|Minimal change nephrotic syndrome|interferon-beta
To our knowledge this is the first report that demonstrates histological abnormalities of the glomerulus associated with postoperative IFN-beta therapy for the malignant melanoma.|histological abnormalities of the glomerulus|IFN-beta
The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.|delayed elimination|ciprofloxacin
The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.|delayed elimination|methotrexate
The authors report two cases of delayed elimination of methotrexate in patients receiving ciprofloxacin, with severe toxicity.|toxicity|ciprofloxacin
CONCLUSIONS: Clinicians should be aware of the possible association of thrombocytopenia with lansoprazole and discontinue the drug if thrombocytopenia becomes apparent.|thrombocytopenia|lansoprazole
DISCUSSION: After exclusion of other causes, the onset of thrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to lansoprazole.|thrombocytopenia|lansoprazole
DISCUSSION: After exclusion of other causes, the onset of thrombocytopenia after administration of lansoprazole, the resolution of the adverse reaction after discontinuation of the drug, and the fact that no other medicines were introduced during this time frame lead us to believe that this was most likely an idiosyncratic thrombocytopenic response to lansoprazole.|thrombocytopenic|lansoprazole
He was started on oral lansoprazole 60 mg twice daily and, on hospital day 2, his platelet count decreased to 102 x 10(3)/mm(3); on hospital day 3, the platelet count was 36 x 10(3)/mm(3).|platelet count decreased|lansoprazole
Lansoprazole-induced thrombocytopenia.|thrombocytopenia|Lansoprazole
OBJECTIVE: To describe a case of thrombocytopenia associated with the administration of lansoprazole.|thrombocytopenia|lansoprazole
To date, this is the first reported case of what appears to be isolated thrombocytopenia associated with lansoprazole.|thrombocytopenia|lansoprazole
Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review.|anaphylactoid reaction|amifostine
The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.|allergic reactions|amifostine
The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.|hypocalcemia|amifostine
The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.|hypotension|amifostine
The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.|nausea|amifostine
The most common side effects associated with amifostine are nausea, vomiting, hypotension, hypocalcemia and allergic reactions.|vomiting|amifostine
The patient suffered a life-threatening anaphylactoid reaction to amifostine.|life-threatening anaphylactoid reaction|amifostine
Agranulocytosis during clozapine therapy.|Agranulocytosis|clozapine
Granulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of clozapine.|agranulocytosis|clozapine
Granulocytopenia and agranulocytosis are considered among the most dangerous adverse effects of clozapine.|Granulocytopenia|clozapine
The female patient received clozapine in a daily dose of 400 mg, which induced agranulocytosis after 2 months.|agranulocytosis|clozapine
The male patient was treated with 225-mg/day clozapine and the time to the diagnosis of agranulocytosis was 6 weeks.|agranulocytosis|clozapine
A 53-year-old man developed NMS without rigidity while taking olanzapine.|NMS|olanzapine
Atypical neuroleptic malignant syndrome associated with olanzapine.|neuroleptic malignant syndrome|olanzapine
CASE SUMMARY: We report the case of a 31-year-old patient hospitalized due to behavioral alterations and treated with oral zuclopenthixol, an antipsychotic from the thioxanthene family, who developed an acute, painful erection.|painful erection|zuclopenthixol
CONCLUSIONS: Priapism is an uncommon but potentially serious adverse effect of zuclopenthixol that practitioners, as with many other antipsychotics, should be aware of.|Priapism|zuclopenthixol
DISCUSSION: The occurrence of priapism in our patient was related to zuclopenthixol.|priapism|zuclopenthixol
OBJECTIVE: To present a single case of zuclopenthixol-induced priapism and a literature review.|priapism|zuclopenthixol
Priapism associated with zuclopenthixol.|Priapism|zuclopenthixol
The capacity of zuclopenthixol to induce priapism is thought to be due to its antagonist activity on alpha-adrenergic receptors.|priapism|zuclopenthixol
After identification of the index patient, additional inquiry revealed that the patient's mother was hospitalized previously for overwhelming sepsis associated with metamizole use.|sepsis|metamizole
Metamizole, a nonsteroidal antiinflammatory agent, is prohibited in the United States because of the risk of agranulocytosis but is widely used in Mexico and other countries.|agranulocytosis|Metamizole
Erythropoietin is beneficial in mitomycin-induced hemolytic-uremic syndrome.|hemolytic-uremic syndrome|mitomycin
We describe a patient who developed HUS after treatment with mitomycin C (total dose 144 mg/m2) due to a carcinoma of the ascending colon.|HUS|mitomycin C
Levofloxacin-induced toxic epidermal necrolysis in an elderly patient.|toxic epidermal necrolysis|Levofloxacin
To our knowledge, this case is the first published report of levofloxacin-induced TEN.|TEN|levofloxacin
A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic.|grand mal seizures|bleomycin
A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic.|grand mal seizures|cisplatin
A 31-year-old female developed multiple episodes of grand mal seizures after combination chemotherapy with cisplatin, vinblastine and bleomycin for germ cell ovarian cancer stage Ic.|grand mal seizures|vinblastine
Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.|Posterior leukoencephalopathy|bleomycin
Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.|Posterior leukoencephalopathy|cisplatin
Posterior leukoencephalopathy following cisplatin, bleomycin and vinblastine therapy for germ cell tumor of the ovary.|Posterior leukoencephalopathy|vinblastine
After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.|hemorrhagic lesion|IL-2
After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.|pancytopenia|IL-2
After 5 days of treatment with IL-2, the patient developed a hemorrhagic lesion that progressed to toxic epidermal necrolysis, as well as grade 4 pancytopenia.|toxic epidermal necrolysis|IL-2
OBJECTIVE: To report a case of cutaneous and hematologic toxicity in a patient treated with IL-2.|cutaneous and hematologic toxicity|IL-2
Subcutaneous IL-2 is safe and well tolerated, with a mortality rate <3%.|mortality rate <3|IL-2
Toxic epidermal necrolysis associated with interleukin-2.|Toxic epidermal necrolysis|interleukin-2
A case of anaphylactoid reaction due solely to the use of Gelofusine in a patient with non-haemorrhagic hypovolaemia is presented, with a discussion on the management and the use of allergy identification jewellery.|anaphylactoid reaction|Gelofusine
Gelofusine allergy--the need for identification jewellery.|Gelofusine allergy|Gelofusine
The authors describe valproate-induced hyperammonemia and mental status changes in an 88-year-old man, the first known reported case in an elderly patient.|hyperammonemia|valproate
The authors describe valproate-induced hyperammonemia and mental status changes in an 88-year-old man, the first known reported case in an elderly patient.|mental status changes|valproate
Valproate-induced hyperammonemia as a cause of altered mental status.|altered mental status|Valproate
Valproate-induced hyperammonemia as a cause of altered mental status.|hyperammonemia|Valproate
Leiomyosarcoma in urinary bladder after cyclophosphamide therapy for retinoblastoma and review of bladder sarcomas.|Leiomyosarcoma|cyclophosphamide
The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride.|NMS|amisulpride
The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride.|NMS|clozapine
The epivodes of NMS occured under treatment with clozapine, risperidone, and amisulpride.|NMS|risperidone
A 73-year-old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL).|cough|fludarabine
A 73-year-old woman presented with fever and cough 2 weeks after completing the third cycle of fludarabine for chronic lymphocytic leukemia (CLL).|fever|fludarabine
Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.|lung disease|Fludarabine
Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.|lung disease|fludarabine
Fludarabine induced lung toxicity must be considered in all patients who develop unexplained lung disease while receiving fludarabine.|lung toxicity|Fludarabine
Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.|Multiple pulmonary nodules|fludarabine
Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.|pulmonary toxicity|fludarabine
This case extends the spectrum of fludarabine pulmonary toxicity to include pulmonary nodules.|pulmonary nodules|fludarabine
This case extends the spectrum of fludarabine pulmonary toxicity to include pulmonary nodules.|pulmonary toxicity|fludarabine
To our knowledge, four cases of interstitial pneumonitis associated with fludarabine have been reported in medical literature.|interstitial pneumonitis|fludarabine
Epoprostenol may be associated rarely with severe erythroderma.|erythroderma|Epoprostenol
Severe erythroderma as a complication of continuous epoprostenol therapy.|erythroderma|epoprostenol
We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.|fever|epoprostenol
We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.|nausea|epoprostenol
We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.|rapidly progressive erythema|epoprostenol
We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.|scaling|epoprostenol
We report a case of a patient with pulmonary hypertension and undifferentiated connective tissue disease who, after 2 months of treatment with epoprostenol, presented with rapidly progressive erythema, scaling, nausea and vomiting, and fever.|vomiting|epoprostenol
A 50-year-old diabetic and hypertensive male patient is reported who had ticlopidine-induced marrow aplasia partially responsive to colony-stimulating factors and corticosteroids, but experienced complete recovery with cyclosporine.|marrow aplasia|ticlopidine
There is no consensus on the treatment of ticlopidine-induced marrow aplasia.|marrow aplasia|ticlopidine
Ticlopidine-induced marrow aplasia treated with cyclosporine.|marrow aplasia|Ticlopidine
A 53-year-old man developed lower leg edema 4 weeks after rosiglitazone was increased from 4 mg once/day to 4 mg twice/day.|lower leg edema|rosiglitazone
A 75-year-old man developed bilateral lower leg edema 6 months after switching from troglitazone to pioglitazone.|bilateral lower leg edema|pioglitazone
A 77-year-old man developed ankle, hand, and facial swelling 2 weeks after starting rosiglitazone.|ankle, hand, and facial swelling|rosiglitazone
Two cases of polymorphic ventricular tachycardia induced by the administration of verapamil against paroxysmal supraventricular tachycardia.|polymorphic ventricular tachycardia|verapamil
Verapamil is widely used for the termination of paroxysmal supraventricular tachycardia (PSVT) with little proarrhythmic effect.|proarrhythmic effect|Verapamil
We describe two cases of PSVT that changed to non-sustained polymorphic ventricular tachycardia after administration of verapamil.|non-sustained polymorphic ventricular tachycardia|verapamil
Epsilon-aminocaproic acid and renal complications: case report and review of the literature.|renal complications|Epsilon-aminocaproic acid
Neonatal mydriasis: intravenous lidocaine adverse reaction.|mydriasis|lidocaine
We present a neonate with a seizure disorder who acutely developed pupillary mydriasis secondary to lidocaine overdose.|pupillary mydriasis|lidocaine
We suggest adding this side effect to the list of untoward effects of lidocaine and to the differential diagnosis of fixed dilated pupils in neonates treated with lidocaine.|dilated pupils|lidocaine
Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin.|acute myeloid leukemia|2-deoxycoformycin
Myelodysplasia terminating in acute myeloid leukemia in a hairy cell leukemia patient treated with 2-deoxycoformycin.|Myelodysplasia|2-deoxycoformycin
To the best of our knowledge only two previous cases of AML have been linked to treatment of HCL with purine analogs, both with 2-chlorodeoxyadenosine.|AML|2-chlorodeoxyadenosine
CONCLUSIONS: Peripheral administration of low-dose vasopressin for septic shock should be discouraged because of the risk of ischemic skin complications.|ischemic skin complications|vasopressin
OBJECTIVE: To describe a case of severe skin necrosis resulting from peripheral intravenous administration of low-dose vasopressin in a patient with catecholamine-resistant septic shock.|skin necrosis|vasopressin
Skin necrosis after extravasation of low-dose vasopressin administered for septic shock.|Skin necrosis|vasopressin
Mitomycin-C induced hemolytic uremic syndrome: a case report.|hemolytic uremic syndrome|Mitomycin-C
Mitomycin-C is used widely in the treatment of malignancies and is associated with serious dose related adverse effects including the occurrence of hemolytic uremic syndrome.|hemolytic uremic syndrome|Mitomycin-C
Although vasculitis has been reported in the course of hairy cell leukaemia, it has only rarely been reported as the consequence of cladribine treatment.|vasculitis|cladribine
Systemic vasculitis complicating hairy cell leukaemia treatment with cladribine.|Systemic vasculitis|cladribine
We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.|systemic vasculitis|cladribine
We describe a 73-year-old woman who developed serious systemic vasculitis with associated thrombocytopenia in the course of treatment with cladribine.|thrombocytopenia|cladribine
Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone.|mammary hyperplasias|D-penicillamine
Drug-induced mammary hyperplasias have been reported as rare complications of D-penicillamine and Neothetazone.|mammary hyperplasias|Neothetazone
Gigantomastia induced by bucillamine.|Gigantomastia|bucillamine
Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia.|giant hypertrophy|bucillamine
Retrospectively, bucillamine was believed to be the cause of the giant hypertrophy because of its structural similarity to D-penicillamine, which was the subject of an abundance of reports of mammary hyperplasia.|mammary hyperplasia|D-penicillamine
The authors report the first case of bucillamine-induced giant mammary hyperplasia.|giant mammary hyperplasia|bucillamine
The authors describe three families in whom the occurrence of FVS in all the siblings strongly suggests hereditary susceptibility to valproic acid-induced adverse outcome.|FVS|valproic acid
The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.|developmental delay|valproate
The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.|distinctive facial appearance|valproate
The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.|fetal valproate syndrome|valproate
The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.|FVS|valproate
The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay.|major and minor malformations|valproate
Valproate embryopathy in three sets of siblings: further proof of hereditary susceptibility.|Valproate embryopathy|Valproate
Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept.|Generalised pustular psoriasis|cyclosporin a
We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.|aggravation of the joint condition|cyclosporin A
We report a 50-year-old male patient with a 15-year history of psoriasis including mutilating psoriatic arthritis, in whom the withdrawal of cyclosporin A induced a generalised pustular exacerbation and a aggravation of the joint condition.|generalised pustular exacerbation|cyclosporin A
The first case concerns a 70-year-old man who developed severe aplastic anemia 7 weeks after treatment with 500 mg of ticlopidine daily.|aplastic anemia|ticlopidine
The second was an 82-year-old man receiving ticlopidine for 2 years when, during a febrile episode, he was found neutropenic with marrow aplasia.|marrow aplasia|ticlopidine
The second was an 82-year-old man receiving ticlopidine for 2 years when, during a febrile episode, he was found neutropenic with marrow aplasia.|neutropenic|ticlopidine
Ticlopidine-induced aplastic anemia (TIAA) is considered very uncommon.|aplastic anemia|Ticlopidine
Ticlopidine-induced aplastic anemia (TIAA) is considered very uncommon.|TIAA|Ticlopidine
Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases.|aplastic anemia|Ticlopidine
When the data of the 57 patients are evaluated, a reversible direct cytotoxic effect of ticlopidine on the pluripotent/bipotent hematopoietic progenitor stem cell is proposed.|cytotoxic effect|ticlopidine
Fixed drug eruption to rofecoxib.|Fixed drug eruption|rofecoxib
Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.|herpetiform fixed drug eruption|Rofecoxib
Rofecoxib, used for dysmenorrhea, caused a herpetiform fixed drug eruption predominantly involving the lips with classic clinical and histological findings in a red-brown lesion on the dorsal hand.|red-brown lesion|Rofecoxib
A patient who had been treated with large doses of thyroid hormone for several years developed features of secondary hypothyroidism after thyroid hormone withdrawal.|hypothyroidism|thyroid hormone
BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.|hemolytic-uremic syndrome|gemcitabine
BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.|hemolytic-uremic syndrome|Gemcitabine
BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.|HUS|gemcitabine
BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.|HUS|Gemcitabine
BACKGROUND: Gemcitabine has mild renal toxicity, but cases of gemcitabine-associated hemolytic-uremic syndrome (HUS) have been reported.|renal toxicity|Gemcitabine
CONCLUSION: There are only a few confirmed cases of gemcitabine-associated HUS despite the widespread use of the drug.|HUS|gemcitabine
Gemcitabine-associated hemolytic-uremic syndrome.|hemolytic-uremic syndrome|Gemcitabine
Mean time between initiation of gemcitabine therapy and onset of HUS was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine.|HUS|gemcitabine
Mean time between initiation of gemcitabine therapy and onset of HUS was 7.4 +/- 3.5 months, or 21.9 +/- 10.9 doses of gemcitabine.|HUS|gemcitabine
METHODS: A case is presented of a 45-year-old woman on prolonged gemcitabine treatment for ovarian cancer who developed HUS and recovered after drug discontinuation.|HUS|gemcitabine
RESULTS: Including our own patient, a total of 26 cases of gemcitabine-associated HUS were identified.|HUS|gemcitabine
An amiodarone optic neuropathy has been described.|optic neuropathy|amiodarone
